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Abstract 
 
Asthma is increasing all over the world particularly in developing countries such as Sudan. Major 
questions for researchers will arise such as is there evidence that asthma is appropriately treated in Sudan; 
is there evidence that the asthmatic patients are provided with the best health care, is the contribution of 
the pharmacists in asthmatic patients care will improve their outcomes. From these questions the 
objectives of this research work were developed, they include the investigation of the current prescribing 
practices for the treatment of chronic and acute attacks of asthma, and the evaluation of the impact of 
implementing a pharmaceutical care service in Sudanese asthmatic patients. 
 
 The present study was conducted at Shaab teaching hospital in Khartoum state. Prescribing practices of 
chronic asthma were investigated through systematic random collection of ١٢٥ prescriptions. It was 
revealed that the minimum information required to be in the prescriptions were missed in many of them. 
The name of the medicine was not clearly written due to bad handwriting or spelling mistakes in ٣٢٪ of 
the prescriptions. The strength of the drug and the quantity to be dispensed were not shown in ٦٨٪ and 
٨٠٫٨٪ of the prescriptions, respectively. The dosage form and the directions for use were not written in 
٣٫٢٪ and ٤٪ of the prescriptions, respectively.  In ٦٩٫٦٪ of the prescriptions the number of drugs 
prescribed was in the range of ١-٢ drugs / prescription, while three and four drugs were prescribed in ٢٤٪ 
and ٦٫٤٪ of the prescriptions, respectively. Potential drug -drug interactions were identified in ١٫٦٪ of the 
prescriptions. The dose of inhaled steroids was written appropriately in ١٣٫٥٪ of the prescriptions. Oral 
steroids dose was inappropriate in ١٥٫٢٪ of the prescriptions. The pattern of prescribing in chronic asthma 
management was of low quality due to the low ratio of prescribing preventors to bronchodilators [٠٫٤]. 
Antibiotics were prescribed in ٣٥٫٢٪ of the prescriptions.  
Management of acute attacks of asthma was investigated through retrospective, systematic random 
collection of ٢٥٠ admission sheets. The results showed that the vital signs (Pulse, Respiratory rate and 
Blood pressure) were not reported in ٣٢٫٤٪ of the collected sample. Full medical history was written in ٤ 
% of the sheets and none of the patients was assessed by the peak expiratory flow rate. The results of 
evaluating the appropriateness of the management of acute attacks as written in the admission sheets 
revealed that oxygen was prescribed for ١٤٫٤ % of the patients without indicating the concentration that 
should be administered to them. Irrational prescribing of nebulized salbutamol and intravenous 
aminophylline was also revealed. The steroids were prescribed in ٩٣٫٢ % of the admission sheets, ٢٠٠ mg 
of intravenous hydrocortisone as single dose not followed by prednisolone was prescribed in ٦٤٫٤٪ of the 
sheets and inadequate dose of ١٠٠ mg hydrocortisone were found in ٢٥٫٤٪ of the sheets. The study 
revealed inappropriate management of acute exacerbations of asthma. 
 
 
 
The study of evaluating the impact of implementing a pharmaceutical care service in Sudanese asthmatic 
patients was carried out in ١٠٠ patients; they were randomly allocated in two groups, control group (٤٠) 
and intervention group (٦٠). The study results have shown that patients in the intervention group had 
better final outcomes than patients in the control group. The intervention patients had significant better 
asthma symptom status, reduction in the occurrence of nocturnal asthma symptoms, the use of inhaled β٢ 
agonists, days of sickness and rate of hospitalization. Although the number of patients in this study was 
small, its findings imply that the pharmacist’s intervention had an effect in terms of improving the quality 
of care for asthmatic patients.  
 
The findings of this study have shown that the patients in the intervention group had better intermediate 
outcomes than those in the control group. The intervention patients had better improvement in the peak 
expiratory flow rate, technique of inhaler use, asthma and drug knowledge, patients’ compliance to drug 
and non-drug therapy and the ratio of prescribing inhaled steroids to bronchodilators. The face-to-face 
education of asthmatic patients in the intervention group facilitated the individual learning needs and 
provided patients interactions and their involvement in decisions regarding their appropriate treatment. 
 
 
In conclusion, the present results pointed out the common prescribing errors in the prescribing practices 
for the treatment of chronic asthma and acute exacerbations of asthma and demonstrated the need for 
establishment of the updated national guideline for the management of asthma, continuing medical 
education, supervision and monitoring of the prescribing practices. Also it showed that the pharmacist 
led-interventions resulted in improved management of the asthmatic patients. The results support the 
value of collaboration between physicians, pharmacists and patients, which improved prescribing, solved 
drug therapy–related problems and improved the quality of care for asthmatic patients. 
 
 
 
   اﻟﺪراﺳﺔﻣﺴﺘﺨﻠﺺ
  
  
هﻨﺎﻟﻚ اﻟﻌﺪﻳﺪ ﻣﻦ اﻟﻤﺸﺎآﻞ اﻟﻤﺘﻌﻠﻘﺔ . آﺎﻟﺴﻮدان ازدادت اﻻﺻﺎﺑﺔ ﺑﻤﺮض اﻟﺮﺑﻮ ﻓﻲ ﺟﻤﻴﻊ أﻧﺤﺎء اﻟﻌﺎﻟﻢ وﺑﺼﻔﺔ ﺧﺎﺻﺔ اﻟﺪول اﻟﻨﺎﻣﻴﺔ 
  . ﺑﻮﺻﻒ اﻷدوﻳﺔ واﻟﻌﻨﺎﻳﺔ اﻟﻄﺒﻴﺔ ﻟﻤﺮﺿﻰ اﻟﺮﺑﻮ 
ﺔ ﻟﻤﻌﺎﻟﺠﺔ اﻟﺮﺑﻮ اﻟﻤﺰﻣﻦ، وﻗﺪ أﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻓﻲ ﻣﺴﺘﺸﻔﻰ اﻟﺸﻌﺐ اﻟﺘﻌﻠﻴﻤﻰ ﺑﻬﺪف أﺳﺘﻘﺼﺎء اﻟﻤﻤﺎرﺳﺎت ﻓﻲ وﺻﻒ اﻷدوﻳ
 وﺻﻔﺔ ﻃﺒﻴﺔ وأﺳﻔﺮت ﻧﺘﻴﺠﺔ اﻟﺘﺤﻠﻴﻞ ﻋﻦ أن آﺜﻴﺮ ﻣﻦ اﻟﻮﺻﻔﺎت اﻟﻄﺒﻴﺔ ﺗﻔﺘﻘﺮ ﻟﻠﻤﻌﻠﻮﻣﺎت ٥٢١ﺟﻤﻌﺖ ﻋﻴﻨﺎت ﻋﺸﻮاﺋﻴﺔ ﻣﻦ 
ﺗﺤﺘﻮى ﻋﻠﻰ اﺧﻄﺎء اﻣﻼﺋﻴﺔ ﻟﻜﺘﺎﺑﺔ اﻷدوﻳﺔ وآﺜﻴﺮًا ﻣﺎ ﻳﻜﻮن اﻟﺨﻂ ﻏﻴﺮ واﺿﺢ ، آﻤﺎ أن ﺗﺮآﻴﺰ اﻟﺪواء % ٢٣اﻻﺳﺎﺳﻴﺔ ﻓﻤﺜًﻼ 
ﻋﻠﻰ اﻟﺘﻮاﻟﻰ، ﺷﻜﻞ اﻟﺼﻴﺪﻻﻧﻰ ﻟﻠﺪواء وﻃﺮﻳﻘﺔ اﺳﺘﺨﺪاﻣﻪ % ٨٫٨١% ٨٦ﺔ ﻣﻨﻪ ﻟﻌﻼج اﻟﻤﺮﻳﺾ ﻏﻴﺮ ﻣﺤﺪدة ﻓﻲ واﻟﻜﻤﻴﺔ اﻟﻤﻄﻠﻮﺑ
  .ﻣﻦ اﻟﻮﺻﻔﺎت ﻋﻠﻰ اﻟﺘﻮاﻟﻰ% ٤و % ٢٫٣ﻏﻴﺮ ﻣﻮﺿﺤﺔ ﻓﻲ 
ﻣﻦ اﻟﻮﺻﻔﺎت ﻋﻠﻰ ﺛﻼﺛﺔ أدوﻳﺔ % ٤٢ﻣﻦ اﻟﻮﺻﻔﺎت دواء واﺣﺪًا إﻟﻰ اﺛﻨﻴﻦ ﺑﻴﻨﻤﺎ اﺣﺘﻮت % ٦٫٩٦آﺎن ﻋﺪد اﻷدوﻳﺔ اﻟﻤﻮﺻﻮﻓﺔ ﻓﻲ 
ﻨﺸﺎق اﻟﺘﻰ ﺗﻌﻄﻰ ﻋﻦ ﻃﺮﻳﻖ اﻻﺳﺘ( sdioretSاﻟﺴﺘﺮوﻳﺪات )ﻣﻦ اﻟﻮﺻﻔﺎت ﻋﻠﻰ أرﺑﻌﺔ أدوﻳﺔ وآﺎﻧﺖ اﻟﺠﺮﻋﺔ ﺑﺎﻟﻨﺴﺒﺔ % ٤٫٦و 
  .ﻣﻦ اﻟﺴﺘﺮوﻳﺪات اﻟﺘﻰ ﺗﻌﻄﻲ ﻋﻦ ﻃﺮﻳﻖ اﻟﻔﻢ% ٢٫٥١ﺑﻴﻨﻤﺎ آﺎﻧﺖ اﻟﺠﺮﻋﺎت ﻏﻴﺮ ﺻﺤﻴﺤﺔ ﻓﻲ % ٥٫٣١ﻏﻴﺮ ﺻﺤﻴﺤﺔ ﻓﻲ 
ﺰﻣﻦ اﻧﺨﻔﺎض ﻧﻮع اﻟﺘﺤﻜﻢ اﻟﻮﺻﻔﻲ ﻻرﺗﻔﺎع ﻧﺴﺒﺔ أﻇﻬﺮت اﻟﺪراﺳﺔ ان اﻟﻤﻤﺎرﺳﺔ ﻓﻲ وﺻﻒ اﻟﺪواء ﺑﺎﻟﻨﺴﺒﺔ ﻟﻤﺮﺿﻲ اﻟﺮﺑﻮ اﻟﻤ
  .اﻻدوﻳﺔ اﻟﻤﻮﺳﻌﺔ ﻟﻠﺸﻌﺐ اﻟﻬﻮاﺋﻴﺔ ﻋﻦ ﺗﻠﻚ اﻟﻮﻗﺎﻳﺔ
 ٠٥٢ﺟﺮﻳﺖ دراﺳﺔ ﻋﻦ ﻃﺮﻳﻖ ﺟﻤﻊ ﻋﻴﻨﺔ ﻋﺸﻮاﺋﻴﺔ ﻣﻜﻮﻧﺔ ﻣﻦ أﻻﺳﺘﻘﺼﺎء اﻟﻤﻤﺎرﺳﺎت ﻓﻲ وﺻﻒ اﻷدوﻳﺔ ﻟﻤﻌﺎﻟﺠﺔ اﻟﺮﺑﻮ اﻟﺤﺎد 
ﻤﺎرات ﻻ ﺗﺤﺘﻮى ﻋﻠﻰ اﻟﻤﻌﻠﻮﻣﺎت اﻷﺳﺎﺳﻴﺔ ﻟﺘﻘﻮﻳﻢ ﻣﻦ اﻻﺳﺘ% ٤٫٢٣ن أاﺳﺘﻤﺎرة ﻟﺪﺧﻮل ﻏﺮﻓﺔ اﻟﻄﻮارئ واﺳﻔﺮت اﻟﺪراﺳﺔ ﻋﻠﻰ 
  .اﻟﻤﺮﻳﺾ ﻣﺜﻞ ﻗﻴﺎس اﻟﻨﺒﺾ وﻣﻌﺪل اﻟﺘﻨﻔﺲ وﺿﻐﻂ اﻟﺪم
  .ﻓﻘﻂ ﻣﻦ اﻻﺳﺘﻤﺎرات اﺣﺘﻮت ﻋﻠﻰ اﻟﺘﻘﺮﻳﺮ اﻟﻜﺎﻣﻞ ﻋﻦ اﻟﺘﺎرﻳﺦ اﻟﻄﺒﻲ ﻟﻠﻤﺮﻳﺾ% ٤
  .ﻣﻦ اﻻﺳﺘﻤﺎرات ﻣﻦ ﻏﻴﺮ ﺗﺮآﻴﺰ ﻣﺤﺪد ﻟﻠﻜﻤﻴﺔ اﻟﺘﻰ ﻳﺠﺐ إﻋﻄﺎؤهﺎ ﻟﻠﻤﺮﻳﺾ% ٤٫٤١آﺴﺠﻴﻦ ﻓﻲ ﻷوﺻﻒ ا
ﻣﻦ اﻻﺳﺘﻤﺎرات ﺣﻴﺚ وﺻﻒ % ٤٫٥٢ﻣﻦ اﻻﺳﺘﻤﺎرات وآﺎﻧﺖ اﻟﺠﺮﻋﺔ ﻏﻴﺮ ﺻﺤﻴﺤﺔ ﻓﻲ % ٢٫٣٩ﺘﺮوﻳﺪات ﻓﻲ وﺻﻔﺖ اﻟﺴ
وﻟﻜﻨﻬﺎ ﻟﻢ ﺗﻜﺘﻤﻞ ﺑﻮﺻﻒ ﻋﻘﺎر % ٤٫٤٦  ﻣﻠﻎ ﺑﻨﺴﺒﺔ٠٠٢ ﻣﻠﻎ ﻣﻦ ﻋﻘﺎر اﻟﻬﻴﺪروآﻮرﺗﻴﺰون ﺑﻴﻨﻤﺎ وﺻﻔﺖ ٠٠١ﻟﻠﻤﺮﺿﻲ 
  .اﻟﺒﺮدﻧﺴﻮﻟﻮن
  
  .ﺳﻔﺮت اﻟﺪراﺳﺔ ﻋﻦ أن اﻟﻤﻤﺎرﺳﺔ ﻓﻲ وﺻﻒ اﻷدوﻳﺔ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻨﻮﺑﺎت اﻟﺮﺑﻮﻳﺔ اﻟﺤﺎدة ﻏﻴﺮ وافأ
 ﻣﺮﻳﺾ ٠٠١ﺗﻄﺒﻴﻖ وﺗﻘﻮﻳﻢ ﺗﺠﺮﺑﺔ اﻟﺮﻋﺎﻳﺔ اﻟﺼﻴﺪﻻﻧﻴﺔ ﻓﻲ ﻣﺮﺿﻲ اﻟﺮﺑﻮ ﻓﻲ اﻟﺴﻮدان أﺟﺮﻳﺖ ﻋﻠﻰ ﻋﻴﻨﺔ ﻋﺸﻮاﺋﻴﺔ اﺣﺘﻮت ﻋﻠﻰ 
 ﻣﺮﻳﺾ ﺑﻴﻨﻤﺎ اﺣﺘﻮت اﻟﻤﺠﻤﻮﻋﺔ ٠٦ﻤﻠﺖ  وﻗﺪ ﺷ)noitnevretnI(وﻗﺪ ﻗﺴﻢ اﻟﻤﺮﺿﻲ ﻣﺠﻤﻮﻋﺘﻴﻦ، ﻣﺠﻤﻮﻋﺔ اﻟﺘﺪﺧﻞ اﻟﺘﻘﻮﻳﻤﻲ 
 ﻣﺮﻳﺾ ، وﻗﺪ اﻇﻬﺮت ﻣﺠﻤﻮﻋﺔ اﻟﺘﺪﺧﻞ اﻟﺘﻘﻮﻳﻤﻲ ﺗﺤﺴﻨًﺎ ذا دﻻﻟﺔ إﺣﺼﺎﺋﻴﺔ واﺿﺤﺔ ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻤﺠﻤﻮﻋﺔ ٠٤ )lortnoC(اﻟﻘﻴﺎﺳﻴﺔ 
اﻟﻘﻴﺎﺳﻴﺔ ﻓﻲ ﺗﻘﻠﻴﻞ ﻣﻌﺪل اﻷﻋﺮاض اﻟﺮﺑﻮﻳﺔ اﻟﻠﻴﻠﻴﺔ ﻓﻲ اﻷﺳﺒﻮع وﻋﺪد أﻳﺎم اﻟﻌﺴﺮ اﻟﻤﺮﺿﻲ ، آﻤﺎ أوﺿﺤﺖ ﺗﻘﻠﻴًﻼ واﺿﺤًﺎ ﻓﻲ 
  . ﺧﻼل اﻷﺳﺒﻮع وﻧﺴﺒﺔ اﻻﺳﺘﺠﻤﺎم)stsinoga ٢β delahnI(ﻬﻼك ﻣﺴﺘﻘﺒﻼت ﺑﻴﺘًﺎ اﻻدرﻳﻨﺮﺟﻴﺔ اﺳﺘ
ﺑﺎﻟﺮﻏﻢ ﻣﻦ أن ﻋﺪد اﻟﻤﺮﺿﻲ ﻟﻬﺬﻩ اﻟﺪراﺳﺔ آﺎن ﻗﻠﻴﻞ ﺟﺪًا ﻟﻜﻦ اﻟﻨﺘﺎﺋﺞ ﺗﻮﺿﺢ اﻟﺘﺪﺧﻞ اﻟﺼﻴﺪﻻﻧﻰ ﻟﻪ ﺗﺄﺛﻴﺮ آﺒﻴﺮ ﻓﻲ ﺗﺤﺴﻴﻦ اﻻهﺘﻤﺎم 
  .ﺑﻤﺮﺿﻲ اﻟﺮﺑﻮ
ﻴﺪﻻﻧﻰ ﻟﻬﺎ ﻧﺘﺎﺋﺞ ﻓﻮرﻳﺔ ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻤﺠﻤﻮﻋﺔ اﻟﻘﻴﺎﺳﻴﺔ وأﻇﻬﺮت ﺗﺤﺴﻨًﺎ واﺿﺤًﺎ أوﺿﺤﺖ اﻟﻨﺘﺎﺋﺞ أن اﻟﻤﺮﺿﻲ ﻟﻤﺠﻤﻮﻋﺔ اﻟﺘﺪﺧﻞ اﻟﺼ
 وﻓﻲ اﺳﻠﻮب اﺳﺘﺨﺪام اﻟﺮذاذات اﻟﻬﻮاﺋﻴﺔ ﻣﻌﺮﻓﺔ اﻟﻤﺮﻳﺾ ﺑﻤﺮض )etar wolf yrotaripxe kaep(ﻓﻲ زﻳﺎدة ﻣﻌﺪل اﻟﺰﻓﻴﺮ 
زادت ﻧﺴﺒﺔ وﺻﻒ اﻷدوﻳﺔ اﻟﻮﻗﺎﺋﻴﺔ آﻤﺎ . اﻟﺮﺑﻮ واﻷدوﻳﺔ اﻟﻤﺴﺘﺨﺪﻣﺔ ﻓﻲ ﻋﻼﺟﻪ وارﺗﺒﺎط اﻟﻤﺮﺿﻲ ﺑﺎﻟﻌﻼج اﻟﺪواﺋﻰ وﻏﻴﺮ اﻟﺪواﺋﻰ
  .ﺑﺎﻟﻨﺴﺒﺔ ﻟﻸدوﻳﺔ اﻟﻤﻮﺳﻌﺔ ﻟﻠﺸﻌﺐ اﻟﻬﻮاﺋﻴﺔ
اﻟﺘﻌﻠﻴﻢ اﻟﻤﺒﺎﺷﺮ ﻟﻤﺮﺿﻲ اﻟﺮﺑﻮ ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻟﺘﺪﺧﻞ اﻟﺘﻘﻮﻳﻤﻲ اﻟﺼﻴﺪﻻﻧﻰ ﻋﻤﻠﺖ ﻋﻠﻰ ﺳﺪ اﺣﺘﻴﺎﺟﺎت اﻟﻔﺮد وزوت اﻟﻤﺮﺿﻲ 
  .ﺑﺎﻟﺘﻜﺎﻣﻞ واﻟﺘﻔﺎﻋﻞ واﺗﺨﺎذ اﻟﻘﺮارات ﺑﺸﺄن ﻋﻼﺟﻬﻢ اﻟﻤﻨﺎﺳﺐ
 وﺻﻒ اﻷدوﻳﺔ ﻟﻌﻼج اﻟﺮﺑﻮ اﻟﻤﺰﻣﻦ واﻟﻨﻮﺑﺎت اﻟﺮﺑﻮﻳﺔ اﻟﺤﺎدة اﻟﺤﻮﺟﺔ ﻟﻮﺿﻊ ﺳﻴﺎﺳﺔ دواﺋﻴﺔ أوﺿﺤﺖ اﻟﻨﺘﺎﺋﺞ أن اﻷﺧﻄﺎء ﻓﻲ
  .ﻗﻮﻣﻴﺔ ﻟﺘﻮﺟﻴﻪ وإدارة اﻟﺘﻌﻠﻴﻢ اﻟﻤﺴﺘﻤﺮ ﻟﻠﻤﺮﺿﻲ واﻻﺷﺮاف واﻟﻤﺮاﻗﺒﺔ ﻟﻠﻮﺻﻔﺎت اﻟﻄﺒﻴﺔ اﻟﺨﺎﺻﺔ ﺑﻤﺮﺿﻰ اﻟﺮﺑﻮ
واﺿﺤﺔ ﻓﻲ اﻟﺘﺤﺴﻦ ﻟﻤﺮﺿﻲ اﻟﺮﺑﻮ اوﺿﺤﺖ اﻟﺪراﺳﺔ ان اﻟﺘﺪﺧﻞ اﻟﺘﻘﻮﻳﻤﻲ اﻟﺼﻴﺪﻻﻧﻰ ﻗﺪ اﺳﻔﺮ ﻋﻦ ﻧﺘﺎﺋﺞ ذات دﻻﻟﺔ اﺣﺼﺎﺋﻴﺔ 
ودﻋﻤﺖ اﻟﻨﺘﺎﺋﺞ ﻗﻴﻤﺔ اﻟﺘﻌﺎون اﻟﻤﺘﺒﺎدل ﺑﻴﻦ اﻷﻃﺒﺎء واﻟﺼﻴﺎدﻟﺔ واﻟﻤﺮﺿﻲ اﻟﺘﻰ ادت اﻟﻰ ﺗﺤﺴﻦ واﺿﺢ ﻓﻲ ﻣﻤﺎرﺳﺎت وﺻﻒ 
   . اﻷدوﻳﺔ وﺣﻞ اﻟﻤﺸﺎآﻞ اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﻤﻌﺎﻟﺠﺔ اﻟﺪواﺋﻴﺔ وﻏﻴﺮ اﻟﺪواﺋﻴﺔ ﻟﻤﺮﺿﻲ اﻟﺮﺑﻮ آﻤﺎ ﺣﺴﻨﺖ ﻣﻦ اﻟﻌﻨﺎﻳﺔ اﻟﻄﺒﻴﺔ ﻟﻤﺮﺿﻰ اﻟﺮﺑﻮ
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Chapter ١ 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ١٫١ Overview of Asthma 
 
١٫١٫١ Definition 
 
Asthma is defined as” a chronic inflammatory disorder of the airways in which many cells play a role, 
particularly mast cells, eosinophils and T lymphocytes. In susceptible individuals, this inflammation 
causes recurrent episodes of expiratory wheezing, breathlessness, chest tightness and cough particularly 
at the night and/or in the morning. These symptoms are usually associated with widespread, but variable, 
airflow limitation that is at least partly reversible, either spontaneously or with treatment. The 
inflammation also causes an associated increase in airways responsiveness to a variety of stimuli”  
This definition was published in ١٩٩٥ following a series of workshops comprising international experts 
as a part of a Global Initiative for Asthma (GINA), sponsored by WHO and the national Institute of 
Health (Ratko and Stephen, ١٩٩٩). 
 
١٫١٫٢ Epidemiology  
 
The exact prevalence of asthma remains uncertain due to the difficulty in defining the disease. Asthma is 
a worldwide problem, which occurs in all races, its prevalence varies from less than ١٪ to as high as ٣٠٪ 
of the populations in different countries.  In ٢٠٠٠, WHO reported that between ١٠٠ and ١٥٠ million 
people around the world suffer from asthma and that worldwide deaths from asthma reached over 
١٨٠،٠٠٠ annually. There is a strong evidence that its prevalence is increasing throughout the world as 
reported by WHO that around ٨٪ of Swiss population suffers from asthma compared to ٢٪ during the 
previous ٢٥-٣٠ years and in USA the number of asthmatics increased by ٦٠٪ since ١٩٨٠s with deaths 
being doubled to ٥،٠٠٠ a year. However, in developing countries the incidence of the disease varies 
greatly .For example in India the number of asthmatics estimated as ١٥-٢٠ million; in Kenya it 
approaches ٢٠٪ of the population; and in Brazil, Costa Rica, Panama, Peru and Uruguay its prevalence in 
children varies from ٢٠٪-٣٠٪(WHO, ٢٠٠٠). This rate of increase in prevalence can be attributed to the 
environmental changes such as increasing exposure to allergens and pollutants rather than genetic factors, 
which cannot be ignored in predisposing individuals to develop asthma (Ratko and Stephen, ١٩٩٩). The 
economic and social impact of asthma is estimated to exceed those of TB and AIDS. The direct costs due 
to hospitalization and drugs accounted for $ ٦٫١ billion dollars in USA, $١٫٨ billion dollars in Britain and 
$ ٤٦٠ million dollars in Australia (WHO, ٢٠٠٠).  
 
 
 
 
١٫١٫٣ Classification of Asthma 
 
a] Allergic Asthma 
It is also known as atopic (allergic) asthma [IgE-mediated], which is triggered by external allergens. It is 
often observed in children and young adults and usually associated with atopic features such as eczema 
and allergic rhinitis.  
 
b] Non-allergic Asthma  
It is also known as non-atopic asthma [non-IgE mediated] of unknown origin, which is triggered by non-
allergenic factors such as viral infections and sensitivity to aspirin. It is usually observed in adults and 
associated with normal level of serum IgE. 
 
• Classification According to Severity (Ratko and Stephen, ١٩٩٩) 
 
This classification is based on clinical features and requirements for treatment, it also combined the 
clinical symptoms, spirometry and, peak expiratory flow (PEF) variation:  
 
i] Intermittent 
• Symptoms < once/ week. 
• Brief exacerbations (from few hours to few days). 
• Night-time asthma symptoms < twice/month. 
• Asymptomatic and normal lung function between exacerbations. 
• PEF or FEV١ > ٨٠٪ of the predicted value; < ٢٠ %variability. 
   
ii] Persistent  
a) Mild Persistent 
• Symptoms > once/ week, but < once/day. 
• Exacerbations may affect activity and sleep.    
• Night-time asthma symptoms > twice/month. 
• PEF or FEV١ > ٨٠٪ of the predicted value, ٢٠-٣٠ % variability. 
 
b) Moderate Persistent  
• Symptoms daily 
• Exacerbations may affect activity and sleep.    
• Night-time asthma symptoms > once/week. 
• Daily use of inhaled short acting β٢ -agonist. 
• PEF or FEV١ > ٦٠٪ - < ٨٠٪ of the predicted value, > ٣٠ % variability. 
c) Severe Persistent 
• Continuous symptoms. 
• Frequent exacerbations. 
• Frequent night-time asthma symptoms. 
• Physical activities limited by asthma symptoms. 
• PEF or FEV١< ٦٠٪ of the predicted value,  > ٣٠ % variability. 
 
١٫١٫٤ Pathophysiology of Asthma 
 
The main features of asthma are marked hypertrophy and hyperplasia of bronchial smooth muscles, 
mucus gland hypertrophy leading to excessive mucus production and inflammatory cell migration, which 
lead to damaged epithelium, mucosal oedema and impaired mucociliary clearance. 
 
A specific cellular defect has not been identified yet but there are a number of pathophysiological features 
that are prevalent in asthma such as a defect in cholinergic activity in the airways, abnormal β-receptor 
adenylate cyclase function that leads to a decrease in adrenergic responsiveness. There is evidence that 
alpha-receptors may trigger bronchoconstriction in some patients (Gibbs and Portlock, ٢٠٠١). 
 
It is thought that the final common pathway in asthma is altered regulation of intracellular calcium due to 
the fact that most of the signs and symptoms of asthma are calcium-dependent processes including the 
release of mediators from mast cells, smooth muscle contraction, mucus secretion, vagus nerve impulse 
conduction and inflammatory cell infiltration (Gibbs and Portlock, ٢٠٠١). 
 
The proposed key mechanism in allergen- induced asthma is the release of mast cell components 
(histamine, leukotrienes, prostaglandins, bradykinins, adenosine, prostaglandin-generating factor of 
anaphylaxis, various chemotactic agents that attract eosinophils and neutrophils) as a result of an IgE 
mediated reaction on the surface of the cell. 
 
The activities of these mediators are described as follows: 
a) Histamine triggers rapid bronchoconstriction. 
b) Leukotrienes (LTs) such as LTC٤, LTD٤, and LTE٤ are potent bronchoconstrictors  
c) Chemotactic agents cause slower reaction characterized by infiltration of macrophages into the lumen   
of the airways that release prostaglandins, thromboxane and platelet activating factor (PAF). 
d) PAF sustains the bronchial hyper- reactivity and causes leakage of plasma from respiratory capillaries 
that increase mucosal oedema. It also facilitates accumulation of eosinophils within the airways. 
e) Eosinophils release various inflammatory mediators such as LTC٤ and PAF resulting in epithelial 
damage and production of thick viscous mucus that causes further deterioration in lung function. 
The mucus production is a normal defense mechanism but in asthmatics it is increased in bronchial glands 
and goblet cells. The mucus transport depends on its viscosity and if it is very thick it plugs the airways, 
which is also blocked by epithelial and inflammatory cell debris. Mucociliary clearance is also decreased 
due to inflammation of epithelial cells. The epithelial cell damage can be severe and can increase access 
of various irritants to cholinergic receptors (Gibbs and Portlock, ٢٠٠١). 
 
١٫١٫٥ Diagnosis  
 
Asthma can present in many ways, the most common is recurrent episodes of difficulty in breathing 
(dyspnoea) associated with wheezing. It can be diagnosed by a combination of a full history from the 
patient or patient’s representative and lung function tests before and after administration of 
bronchodilators. The history of an asthmatic patient often includes the presence of atopy and 
allergic rhinirtis in the patient or within the close relatives. Improvement of chest tightness, 
shortness of breathing and abnormal lung function test by ١٥٪ after administration of a suitable 
bronchodilator will confirm its diagnosis. However, if there is no improvement in ventilation this cannot 
rule out asthma (Gibbs and Portlock, ٢٠٠١).   
 
As well as other respiratory diseases such as chronic obstructive airways disease (COAD) asthma can be 
assessed by a series of routine tests, but the most useful and reproducible test is the FEV١/FVC ratio. 
Forced expiratory volume (FEV) can be measured when the patient inhales as deeply as possible and then 
exhales as forcefully and completely as possible into a mouthpiece connected to the spirometer. FEV١ is a 
measure of the forced expiratory volume in the first second of exhalation. Forced vital capacity (FVC) is 
another volume that is commonly measured and it is the maximum volume of air exhaled with maximum 
effort after maximum inspiration. Normal individuals can exhales at least ٧٥٪ of their total capacity in 
one second and any reduction indicates deterioration in lung performance (Gibbs and Portlock, ٢٠٠١). 
 
The peak flow meter is a useful means of self-assessment for the patient. Although its results are less 
reproducible than the spirometer but it can be used to assess the improvement or deterioration in the 
disease as well as the effectiveness of the treatment. It measures peak expiratory flow rate (PEFR), which 
is the maximum flow rate that can be forced during expiration (Gibbs and Portlock, ٢٠٠١). 
 
The normal values for FEV١, FVC and PEFR, which are compared with those of the patient, vary with 
age, race, gender, height and weight. The three measurements do not detect early deterioration of lung 
function and mucus plugging in the small airways; the diagnosis is usually confirmed by the response to a 
bronchodilator. Assessment of partial pressure of oxygen PaO٢ (reference range١٢-١٦ kPa) and carbon 
dioxide PaCO٢ (reference range ٤٫٦ - ٦٫٠ kPa) in arterial blood, together with PH reference range ٧٫٣٥-
٧٫٤٥) are routinely monitored in patients hospitalized with severe acute asthma (Gibbs and Portlock, 
٢٠٠١). 
١٫٢ Treatment of Asthma 
 
١٫٢٫١ Aims of Treatment  
 
i] To control symptoms, minimize anxiety and permit normal life as possible. 
ii] To educate the patient about the disease and its treatment. 
iii] To identify trigger factors, thus minimizing morbidity and mortality. 
 
١٫٢٫٢ General Measures 
 
i] Environmental control as far as possible. 
ii] Smoking cessation in both patients and their families. 
iii] Stress reduction by effective treatment and educating patients about their disease. 
iv] Prompt control of common cold and infection. 
v] Physiotherapy: the humid atmosphere of swimming bath helps to avoid exercise induced attacks. 
vi] Counseling of the patients to understand the nature of the disease and how to prevent the 
exacerbations and manage them effectively.  
 
١٫٢٫٣ Pharmacotherapy 
 
Asthma is a potentially life-threatening disease that is often under-treated. In the management of asthma, 
there are common therapeutic problems, which are reported such as its under-diagnosis especially in the 
elderly, failure of the avoidance or reduction of allergens, poor patient knowledge about asthma and its 
management, the use of anti-inflammatory therapy on as required basis rather than regularly, missing the 
signs of rapidly deteriorating asthma by the patients or health professionals, incorrect technique in the use 
of inhalers (Gibbs and Small, ٢٠٠٣).  
 
Drug therapy is directed towards reducing inflammation and increasing bronchodiltation. Table [١] shows 
a general approach to the treatment of target features in asthma. The main goals of treatment are 
restoration of normal airways function and prevention of severe acute attacks. The choice of the drug 
therapy of asthma depends on the frequency and severity of the patient’s symptoms (Gibbs and Portlock, 
٢٠٠١). The guidelines for the management of chronic asthma in adults and children as recommended by 
The British Thoracic Society in ١٩٩٧ will be discussed in the introduction of the study for the assessment 
of treatment for chronic asthma (chapter ٢). Management of acute severe attacks will be discussed in the 
introduction of the study for the assessment of emergency treatment of asthma (chapter ٣). 
 
 
Table [١٫١] General Approach to the Treatment of Target Features in Asthma 
 
Target Feature Therapeutic Aim Drugs Used  Examples 
١) Inflammation and 
bronchial hyper-
reactivity 
a) Reduce  
• eosinophil recruitment and 
activation 
• lymphocyte activity 
• toxicity to epithelial cells 
 
 
b) Reduce mast cell degranulation 
Corticosteroids 
 
 
 
 
 
 
Inhibitors of 
mediator release 
Beclomethasone 
Budesonide 
Prednisolone 
 
 
 
 
Sodium cromoglycate  
Nedocromil sodium  
Theophylline (?) 
Selective β٢ agonist 
 
٢)Bronchoconstriction 
 
Bronchodilatation 
a) Increase sympathomimetic 
activity 
 
 
 
 
b) Block parasympathetic activity 
 
 
b) Increase cAMP levels in 
bronchiolar muscle cells 
 
 
Selective β٢ agonist 
 
 
 
 
 
Antimuscarinic 
 
 
Phosphodiesterase 
inhibitor 
 
 
Short-acting: Salbutamol, 
Terbutaline, Fenoterol, 
Reproterol, 
Long-acting: Salmeterol, 
Bambuterol, Eformoterol 
 
Ipratropium, Oxitropium 
 
 
Aminophylline  
Theophylline  
 
(?) : Their precise mode of action is unknown, possible or secondary action 
 
 
 
 
 
 
 
 
١٫٢٫٤ Drugs used in Treatment of Asthma 
 
I] Selective β٢-Adrenergic Receptors Agonists 
 
Pharmacodynamics 
 
The stimulation of β٢-receptors in the bronchioles leads to the activation of adenylyl cyclase resulting in 
increased levels of intracellular cAMP and consequent bronchodilatation (Johnson and Coleman, ١٩٩٥).  
Also they have been shown to increase potassium channels conduction in airway muscle cells leading to 
membrane hyperpolarization and relaxation, this mechanism is independent of adenylyl cyclase activity 
and cyclic AMP (Kume et al., ١٩٩٤).  
 
There are secondary beneficial effects when long acting β٢ agonists used in prophylaxis, they exert anti-
inflammatory effect through the inhibition of the function of some inflammatory cells by elevating the 
intracellular cAMP that leads to the inhibition of the release of the inflammatory mediators and cytokines 
(Lichtenstein and Margolis, ١٩٦٨).  
     
Pharmacokinetics 
 
Short-acting β٢ agonists when given by inhalation have an onset of action within ١-٥ minutes and produce 
bronchodilatation that lasts for about ٢-٦ hours, but when given orally their duration is ٤-٨ hours. The 
preferable- route of administration is the inhalation. 
Long acting β٢-agonists mainly used in asthma prophylaxis, they provide persistent bronchodiltation 
lasting over ١٢ hours.  
 
Side Effects: 
 
Side effects are common when administered orally, parentrally or through excessive inhalation. These 
include skeletal muscle tremors, tachycardia, restlessness, apprehension and anxiety. Increased plasma 
free fatty acids, glucose and lactate, hypokalemia and exacerbation of angina are associated with high 
doses. 
 
Precautions 
 
Beta٢-agonists should be used with caution in patients with hyperthyroidism, cardiovascular disease, 
arrhythmia and hypertension. They should be used with caution in pregnancy and breast-feeding, but the 
benefit of asthma control outweighs any slight effects on mother or fetus. Blood glucose of diabetics 
should be monitored for the risk of ketoacidosis especially when administered intravenously.  
Drug interactions 
 
i] Corticosteroids:Increased risk of hypokalemia with high dose β٢-agonists. 
ii] Theophylline: Increased risk of hypokalemia with high dose β٢-agonists. 
iii] Beta-blockers: Antagonize the bronchodilating effect of β٢-agonists. 
 
Dosage 
i] Salbutamol  
• Aerosol Inhalation: ١٠٠-٢٠٠ug (١-٢ puffs) up to ٣-٤ times daily for persistent symptoms.                                   
• Nebulized Solution Inhalation: Adult and child over ١٨ months ٢٫٥ mg repeated up to ٤ times 
may be increased to ٥ mg if necessary.  
• Oral: Adult (٦-١٦mg in ٣-٤ divided doses/day). >٢years (٤٠٠µg /kg in ٤ divided doses/day); ٢-
٦years (٣-٨mg in ٣-٤ divided doses/day); ٦-١٢ years (٦-٨mg in ٣-٤ divided doses). 
ii] Terbutaline 
• Aerosol Inhalation: ٢٥٠-٥٠٠ug (١-٢ puffs) up to ٣-٤ times daily for persistent symptoms. 
• Nebulized Solution Inhalation: Adult (١٠-٤٠mg in ٢- ٤ divided doses daily); up to ٣years (٢ mg); 
٣-٦years (٣mg); ٦-٨years (٤mg) ;>٨years (٥mg) ٢-٤ times daily. 
• Oral: initially ٢٫٥ mg ٣ times daily for ١-٢ weeks, then up to ٥mg ٣ times daily. Child ٧٥ µg /kg 
٣ times/daily; ٧-١٥ years ٢٫٥ mg ٢-٣ times daily. 
iii] Salmeterol 
• Aerosol Inhalation:  ٥٠ µg (٢ puffs) twice daily up to ١٠٠µg (٤ puffs) twice daily in more severe 
airways obstruction. Child under ٤ years not recommended, > ٤ years ٥٠ µg (٢ puffs) twice daily. 
 iv] Eformoterol  
• Inhalation of powder: Adult and child > ١٢ years ٦-١٢µg once or twice daily. 
  
II] Antimuscarinic Bronchodilators 
 
Pharmacodynamics 
 
They competitively and selectively block the action of acetylcholine at the muscarinic receptors in the 
lungs, reducing cGMP and hence decreasing muscle tone and producing dilatation of both larger and 
small airways. A synergistic bronchodilating effect is produced when they are combined with β٢-agonists; 
this effect is of great importance in emergency treatment of acute asthma exacerbations (Bryant and 
Roger, ١٩٩٢). They are useful in older, chronic asthmatics with decreased responsiveness to β٢-agonists; 
also they are more effective in relieving bronchoconstriction associated with chronic obstructive 
pulmonary disease.  
 
 
Pharmacokinetics 
 
The aerosol inhalation of ipratropium has maximum effect ٣٠-٦٠ minutes after use with duration of 
action of ٣-٦hours and its effect maintained by administration three times a day. 
 
Side Effects 
 
Acute angle- closure glaucoma has been reported in patients given nebulised ipratropium .Dry mouth; 
urinary retention and constipation are rarely reported. 
 
Dosage 
 
Ipratropium 
• Aerosol Inhalation: Adult ٦٠-٣٢٠ µg in ٣-٤ divided does daily. 
                                Child ٢٠-١٢٠ µg in ٣-٤ divided doses. 
• Nebulized Solution Inhalation:   Adult ١٠٠-٥٠٠ µg up to four times daily. 
                                                      Child  ٣-١٤years ١٠٠-٥٠٠µg in up to ٣ times daily 
 
III] Theophylline 
 
Pharmacodynamics 
 
The mechanism of action of theophylline may be through inhibiting cyclic nucleotide phosphodiesterase 
enzymes (PDEs), which lead to accumulation of cAMP in cells and causing airways relaxation. It is also a 
competitive antagonist at adenosine receptors that mediate adenosine-induced bronchospasm (Fredholm 
and Person, ١٩٨٢). Adenosine is known to cause bronchoconstriction in asthmatics and potentiate 
immunologically induced mediator release from human lung mast cells (Cushley et al., ١٩٨٤; Peachell et 
al., ١٩٨٨). 
 
Other actions of theophylline include the direct effects on intracellular Ca٢+ concentration and indirect 
effect via cell membrane hyperpolarization and the uncoupling of intracellular Ca٢+ from muscular 
contraction. There is evidence that cAMP modulation of intracellular Ca levels, may be a common 
pathway for bronchodilatation. The action of theophylline to mobilize intracellular Ca٢+ may prove to be 
its principal effect (Gibbs and Small, ٢٠٠٣). 
 
Theophylline is the most potent bronchodilator used for reversible airways obstruction and the treatment 
of acute severe asthma (Fanta et al., ١٩٨٦; Rossing et al., ١٩٨٠). Nocturnal asthma can be improved with 
slow-release theophylline preparations (Self et al., ١٩٩٢). Now the role of theophylline in treatment of 
chronic asthma is far less prominent due to its narrow therapeutic index and the requirement for 
monitoring of its plasma levels (Stoloff, ١٩٩٤; Nasser and Rees, ١٩٩٣). 
 
Pharmacokinetics 
 
Methylxanthines are absorbed readily from oral and parentral administration. Absorption from rectal 
suppositories is slow and unreliable but it is absorbed completely from liquids, uncoated tablets and some 
but not all sustained–release preparations (Hendeles and Weinberger, ١٩٨٢). Its maximal plasma 
concentration is achieved within ٢ hours after the administration of uncoated tablets in an empty stomach. 
 
Sustained release preparations designed to provide therapeutic plasma levels that persist over about ١٢ h, 
peak levels tend to occur after about ٨ hours, thus the evening dose should be taken at about ٨ p.m to 
control nocturnal asthma and early morning wheezing. The use of short-acting oral formulations should 
be discouraged due to the high incidence of adverse effects associated with their rapid release and 
absorption; and their highly variable clearance. They also provide unpredictable and short duration of 
action (Gibbs and Small, ٢٠٠٣). 
 
Its elimination half-life is increased in heart failure, liver cirrhosis, viral infection, elderly and 
concomitant administration with hepatic microsomal enzyme inhibitors. Its elimination half-life is 
decreased in smokers, chronic alcoholism and concomitant administration with hepatic microsomal 
enzymes inducers. These changes in half-life are very important as theophylline has a narrow therapeutic 
index; in most subjects ١٠-٢٠mg/L plasma concentration is required for satisfactory bronchodilation, 
although ١٠mg/L or less may be effective, but side effects may occur at plasma level of ٢٠mg/L. The 
amount of drug excreted renally is only ١٠٪, thus renal impairment should not affect blood levels 
significantly unless there is renal failure (Gibbs and Small, ٢٠٠٣). 
 
Theophylline is used parenterally as aminophylline (a mixture of theophylline with ethylenediamine) that 
has ٢٠ times higher solubility than theophylline. It must be given very slowly through intravenous 
injection over a minimum of ٢٠ minutes; it is preferable to be administered as a low volume by 
intravenous infusion (BNF, ٢٠٠٢). 
 
Side Effects 
Headache, nausea, palpitation, dizziness, hypotension and pericardial pain are reported. Persistent emesis, 
severe restlessness, agitation, gastrointestinal bleeding and cardiac arrhythmias are the side effects 
associated with plasma concentrations over ٢٠mg/L. Hyperglycemia, hypotension, more life-threatening 
cardiac arrhythmias, convulsions, permanent brain damage and death may occur at concentrations above 
٣٥ mg/L. Individual patients may suffer from these side effects at serum concentrations other than those 
quoted e.g seizures occurred in patients at ٢٥ mg/L (Gibbs and small, ٢٠٠٣). 
Therapeutic Drug Monitoring: 
 
Theophylline has a narrow therapeutic –index and its hepatic metabolism vary between individuals 
therefore, the serum levels of the drug should be monitored. The samples should be taken at steady state 
approximately ٤-٦hours after starting the infusion and ٨-١٢hours after an oral dose of modified release 
product. Serum level should be adjusted between ١٠-٢٠mg/L. However, some patients show clinical 
responses at levels less than ١٠mg/L others tolerate levels more than ٢٠mg/L. 
 
Only modified release preparations should be used and once the patient is stabilized on a particular 
product it should not be changed to another because there is differences in serum profiles of different 
heophylline preparations. Normal-release theophylline preparations should not be used as they show rapid 
absorption, highly variable clearance, and short and unpredictable duration of action (Gibbs and Portlock 
٢٠٠١). 
  
Precautions 
 
It should be used with caution in patients with cardiac disease, hypertension, hyperthyroidism, peptic 
ulcer, hepatic impairment, epilepsy, also in pregnancy, breast-feeding and elderly. It should be avoided in 
porphyria. 
 
Drug Interactions  
 
Cimetidine, erythromycin, oral contraceptives, ciprofloxacin and propranolol decrease theophlline 
metabolism, thus increasing its serum level and toxicity. Carbamazepine, phenobarbitone, phenytoin,  
sulphinpyrazone increase its hepatic metabolism, thus decreasing its serum level and efficacy. 
 
Dosage  
 Oral             Adult      ٢٥٠-١٠٠٠ mg (modified release) in ١-٢ divided doses. 
                     Child       ١٠-١٢ mg/kg (modified release) in ١-٢ divided doses. 
 
Intravenous Aminophylline dosing in Acute Severe Asthma (BNF, ٢٠٠٢) 
 Total daily dosage range Patient Characteristics 
Intravenous Injection ٥ mg/kg as a single dose Adults and children 
 
 
Intravenous Infusion ٠٫٥ mg/kg/h 
١ mg/kg/h 
٠٫٨ mg/kg/h 
Adults 
Child ٦ months-٩ years 
Child ١٠ – ١٦ years 
IV] Corticosteroids 
 
Pharmacodynamics 
 
They stimulate the synthesis of the protein [lipocortin], which inhibits phospholipase A٢ enzyme activity, 
eventually inhibits the synthesis of prostaglandins and leukotrienes in macrophages, monocytes and mast 
cells. They block the production and release of the potent inflammatory cytokines and also the formation 
of complement C٣ acute phase reactants. They reduce the extravasation of lymphocytes, fibrosis and 
production of platelet activating factor and IgE. All these effects are combined to decrease the 
inflammatory damage in the airways and the hyper-reactivity resulting in decreased oedema and secretion 
of mucus into the airway. 
 
Inhalational therapy with corticosterids is used in asthma prophylaxis, being highly effective in 
controlling the delayed inflammatory response. Alleviation of symptoms usually occurs ٣-٧ days after 
starting therapy with a maximal response during ٧-١٤ days or more. They are introduced earlier in the 
management of asthma if there are significant nocturnal symptoms or more than three wheezy episodes 
per week or if short-acting β٢-agonists are used more than once daily. 
 
Oral corticosteroids are used as a last resort in chronic asthma to provide adequate control of symptoms. 
The minimum effective dose must be used to avoid their side effects as far as possible. Their immediate 
use to abort a severe attack may be invaluable. Prednisolone in doses of about ٣٠-٤٠ mg may be needed 
initially depending on the severity of symptoms, after the patient being stable, it may be decreased 
gradually over ٢-٣ weeks to an appropriate maintenance dose or rapidly over a few days, this will depend 
on the duration and intensity of rescue treatment. The treatment should be continued until the dose 
reduction does not lead to relapse. Alternate-day dosing is usually unsuitable in asthma because patients 
tend to deteriorate in the second ٢٤hours period. 
 
Hydrocortisone or methylprednisolone up to ١g daily are administered parenterally in acute severe asthma 
with change to the oral therapy as the patient improves. Nevertheless, it is reported that oral dosage of ٤٠ 
mg prednisolone may be of similar efficacy (Gibbs and Small, ٢٠٠٣). 
 
Side Effects 
 
i] Oral Corticosteroids 
 
Mineralocorticoid effects include: hypertension, hypokalemia, muscle weakness, sodium and water 
retention. These effects are significant with hydrocortisone, slightly occur with prednisolone and 
methylprednisolone and negligible with dexamethasone and betamethasone. 
Glucocorticoid effects include: precipitation of diabetes, osteoporosis, depression, euphoria, peptic 
ulceration, immunosuppression, Cushing’s syndrome, growth suppression in children, worsening of 
infection, skin thinning, striae a trophic, increased hair growth, perioral dermatitis and acne. 
 
Adrenal suppression occurs with high doses and/or prolonged treatment. Steroid therapy must be 
gradually withdrawn in these patients to permit recovery from adrenal suppression and the resumption of 
adequate endogenous cortisol secretion. Adrenal crisis of hypotension, weight loss, arthralgia and 
sometimes death will result if not withdrawn gradually after prolonged use or high doses. 
 
ii] Inhaled Corticosteroids 
 
Few and minor adverse effects: the most common being mild throat irritation and hoarseness (dysphonia). 
The oral deposition of drug may sometimes cause oral thrush. These effects are largely prevented by 
twice daily administration that is effective as that given ٤ times daily; by rinsing the mouth with water or 
mouthwash after using the inhaler, and using a spacer device. Toothbrushes have been reported to be 
reservoir of candida infection in patients using inhaled corticosteroids; patients should be advised to 
change their toothbrush if they develop hoarseness or significant sore throat during treatment. If thrush 
occurs, it is controlled with topical miconazole or nystatin.  
 
Although adverse systemic effects are unlikely unless the daily dose exceeds ١٥٠٠-٢٠٠٠ ug (higher 
doses) of inhaled steroids, small increased risk of glaucoma with prolonged high doses of inhaled 
corticosteroids and cataracts have also been reported. 
 
Nebulized steroids given with facemask may cause facial eczema, this may be largely prevented by 
coating skin under mask with soft paraffin and washing face after dosing. 
 
Relative Contraindications:                                                                   
 
Hypertension, Obesity, Diabetes Mellitus, peptic Ulceration, Psoriasis, Pregnancy, Childhood and 
intercurrent infection especially tuberculosis. 
  
Drug Interactions: 
                                                                                
• Corticosteroids antagonized the effect of antidiabetic agents due to their hyperglycaemic activity. 
• Corticosteroids antagonized the effect of antihypertensive drugs. 
• Corticosteroids increased risk of hypokalemia with high doses of β-agonists. 
• Carbamazepine, Phenobarbitone, Phenytoin and Rifampicin reduced steroid effect due to 
increased metabolism. 
Dosage (Inhalation Therapy) For drugs registered in Sudan:                                                      
 
Beclomethasone Diproprionate, Budesonide, Fluticasone (see Table ٢). 
 
 
V] Cromolyn Sodium and Nedocromil Sodium 
 
Pharmacodynamics 
 
They act by different mechanisms; they inhibit mediators release from mast cells (Pearce et al., ١٩٨٩), 
reverse the increased functional activation in leukocytes and posses the ability to suppress the activating 
effects of chemotactic peptides on human neutrophils, eosinophils, and monocytes (Murphy and Kelly, 
١٩٨٧). 
 
Other reported mechanisms of their action include their inhibition of parasympathetic and cough reflexes 
(Hargreaves and Benson, ١٩٩٥; Fuller et al., ١٩٨٧); and leukocyte trafficking in asthmatic airways 
(Hoshino and Nakamura, ١٩٩٧). 
 
Cromolyn and Nedcromil are used as a preventive therapy in mild to moderate asthma but they 
are ineffective in treating ongoing bronchoconstriction. Nedcromil is more effective than 
Cromolyn in animal models and human studies (Brogden and Sorkin, ١٩٩٣). There is evidence 
that regular use for ٢-٣ months reduce bronchial hyper-reactivity (Murphy and Kelly, ١٩٨٧; 
Hoag and McFadden, ١٩٩١) 
 
Pharmacokinetics 
 
They are given by inhalation (aerosol spray, nebuliser or turbo-inhaler), only ١٪ is absorbed and excreted 
unchanged in urine and bile equally. Peak plasma concentration occurs within ١٥ minutes of inhalation, 
and the half-life range from ٤٥ to ١٠٠ minutes.  
 
Side Effects 
 
Side effects are minor and infrequent, they include bronchospasm, cough, wheezing, laryngeal oedema 
and angioedema. Headache, anaphylaxis, joint pain and swelling, rash, nausea and bad taste are also 
reported. These reactions reported at frequency of less than ١ in ١٠،٠٠٠ patients ((Murphy and Kelly, 
١٩٨٧). 
 
 
Dosage 
 
Sodium Cromoglycate  
Aerosol Inhalation: Adult and Child    ١٠ mg (٢ puffs) ٤ times daily increased in severe cases or during 
periods of risk ٦-٨ times  
 
Nedocromil Sodium 
Aerosol Inhalation: Adult and child over ٦ years ٤mg (٢ puffs) ٤ times daily, when control is achieved 
may be reduced to twice daily.     
 
 
VI] Leukotrienes Modifying Drugs 
 
Pharmacodynamics 
 
These drugs act by two different mechanisms: 
 
i] Leukotriene –receptors antagonists e.g., Montelukast and Zafirlukast. They are selective, high affinity, 
competitive antagonists of cysteinyl leukotrienes receptors (cys-LT١) (Krell et al., ١٩٩٠; Johnes et al., 
١٩٩٥). Cysteinyl leukotrienes are potent bronchoconstrictors including LTC٤ LTD٤, and LTE٤.  
 
ii] Leukotrienes – synthesis inhibitors e.g., Zileuton, which is a potent selective inhibitor of ٥-
lipoxygenase enzyme that produce leukotrienes from arachidonic acid. 
 
These drugs are not indicated for rapid bronchodilator therapy, so the patients are instructed to have their 
available rescue medications such as β٢-agonists. They are used in prophylactic treatment of mild asthma 
but their role in moderate and severe asthma is not adequately assessed yet. Some clinical trials have 
demonstrated that the use of Leukotriene antagonists allow reduction of the dose of inhaled steroid 
needed for control of asthma exacerbations (Lofdhal et al., ١٩٩٩; Jarvis and Markham, ٢٠٠٠). 
 
Pharmacokinetics 
These drugs are available for oral administration in tablets form and they are rapidly absorbed. 
Zafirlukast has bioavailability greater than ٩٠٪and it is over ٩٩٪ protein bound. It is metabolized by the 
liver cytochrome P٤٥٠ isozyme CYP٢C٩; it is half-life is approximately ١٠ hours. 
Montelukast has bioavailability ٦٠-٧٠٪ and its protein binding approach ٩٩٪. It is metabolized by the 
liver cytochrome P٤٥٠ isozyme CYP٣A٤ and CYP٢C٩ and its half-life between ٣-٦hours. 
Zileuton extensively metabolized by cytochrome P٤٥٠ isozymes and by UDP-glucronosyltransferases, it is 
short acting with half-life of ٢٫٥ hours (Joel and Lee, ٢٠٠١). 
 Side Effects 
 
Montelukast and Zafirlukast may cause in very rare instances systemic eosinophilia and vasculitis similar 
to Churg -Strauss syndrome. Zileuton may cause elevation of liver enzymes in the first two months of 
therapy. 
 
Drug Interactions 
 
• Aspirin increases the plasma concentration of zafirlukast. 
• Erythromycin, terfenadine, phenobarbitone, theophylline reduce the plasma concentration of 
zafirlukast. 
• Zafirlukast enhances warfarin effect. 
• Zafirlukast possibly increases plasma theophylline concentration. 
 
Dosage 
 
Montelukast: Adults (١٠ mg daily at bed time); Child (٢-٥ years: ٤ mg daily at bed time; ٦-١٤ years ٥mg 
daily at bed time). 
Zafirlukast: Adults (٢٠ mg twice daily); Child (under ١٢ years not recommended). 
 
 
١٫٣  Pharmaceutical Care 
 
١٫٣٫١ Evolution of the Pharmaceutical Care Concept 
 
The philosophy of pharmaceutical care is now accepted worldwide as the primary mission of pharmacy. It 
was first generated by clinical pharmacists in the United States of America (USA) to describe the patient-
oriented services that the pharmacist should offer. Clinical pharmacists provide pharmaceutical care 
through using all their knowledge and skills to benefit the patient, over a course of time. This level of care 
and work with patients is beyond the traditional pharmacist-patient interaction. It reaches beyond the 
training received in many faculties of pharmacy, which have not updated their undergraduate curriculum 
to cope with the re-professionalization of the pharmacist. Pharmaceutical care is an informational 
partnership between patients and pharmacists; it ensures the achievement of the patient’s desired health 
care outcomes through a collaborative process with physicians and other health care providers, and 
provides patients with better understanding of their health status and drug therapy so they can take better 
health informed decisions.  
 
In ١٩٨٦, a publication entitled Drugs Don’t Have Doses-People Have Doses!, Cipolle defines the role of 
the pharmacist as a “clinical problem solver”. In ١٩٩٠, Hepler and Strand defined pharmaceutical care as 
“the responsible provision of drug therapy for the purpose of achieving definite out comes that improve a 
patient’s quality of life”. In ١٩٩٣, the American Society of Health-System Pharmacists (APhA) statement 
provided an adaptation of the definition developed by Hepler and Strand and defined pharmaceutical care 
as “The mission of the pharmacist is to provide Pharmaceutical care, which is the direct, responsible 
provision of medication-related care for the purpose of achieving definite outcomes that improve a 
patient’s quality of life”  
 
The following are principle elements of pharmaceutical care: - 
i] It is medication related: it involves not only the actual provision of medication but also decisions about 
medication use for individual patients. As appropriate, this involves decisions not to use medication 
therapy as well as judgments about medication selection, dosages, routes, and methods of administration, 
medication therapy monitoring, and the provision of medication-related information and counseling to 
individual patients.  
 
ii] It is care that directly provided to the patient: overall patient care consists of integrated domains of care 
including medical care, nursing care, and pharmaceutical care. Health professionals in each of these 
disciplines possess unique expertise and must cooperate in the patient’s overall care. Through 
pharmaceutical care, the pharmacist contributes unique knowledge and skills to ensure optimal outcomes 
from the use of medications. The pharmacist cooperates directly with other professionals and the patient 
in designing, implementing and monitoring a therapeutic plan intended to produce definite therapeutic 
outcomes that improve the patient’s quality of life. 
 
iii] It is provided to produce definite outcomes; the medication-related therapeutic outcomes sought are 
cure of a patient’s disease, elimination or reduction of a patient’s symptomatology, arresting or slowing of 
a disease process, and preventing a disease or symptomatology (Oddis, ١٩٩٢).  This, in turn, involves 
three major functions: [١] identifying potential and actual medication-related problems, [٢] resolving 
actual medication-related problems, and [٣] preventing potential medication-related problems. A 
medication-related problem is an event involving drug therapy that is actually or potentially affecting the 
optimum outcome for a specific patient. The medication related problems include, untreated medical 
problem, inappropriate drug selection, subtherapeutic dosage, over dosage, failure to receive medication, 
adverse drug reactions, drug-interactions and the use of medication without a valid indication (Helper and 
Strand, ١٩٩٠). 
 
١٫٣٫٢ Barriers to Pharmaceutical Care Implementation (Rovers et al., ١٩٩٨) 
 
Several articles have been published about barriers that impede the implementation of pharmaceutical 
care in a variety of settings, these include 
 
I] Attitudes of Pharmacists: 
  
Unfortunately, some pharmacists do not accept the due to lack of confidence in their abilities and fear of 
change to incorporate the concept into their practice. Others have misconceptions that patients will not 
accept this type of care and that it will create problems with other health care providers. The obstacle of 
fear can be overcome through believing in their knowledge and skills, and the adoption of “a one patient 
at a time” philosophy, this will allow them to develop the skills and knowledge overtime, and to build a 
pharmaceutical care practice with confidence. When pharmacists offer services that satisfy patients’s 
need, overtime, patients will realize the benefits of pharmaceutical care and will tell others. Studies 
proved that when pharmacists focus on establishing professional relationships with other health care 
providers, the potential for hostility subsides.  
 
II] Lack of Advanced Practice Skills   
 
Many of the current practitioners lack the advanced practice skills in therapeutics, clinical problem 
solving, communication, documentation and research. Pharmacists must feel confident about the skills 
they already have and exert effort into building those that are weak. Pharmacists must expand their 
therapeutic knowledge that may be achieved through programs offered by faculties of pharmacy and 
accredited continuing education providers. Development of an increased understanding of therapeutics 
and drug information skills with appropriate training and practice will make clinical problem solving less 
difficult and a natural process. Participating of pharmacists in educational programs on interpersonal 
communication will provide the pharmacist with strong communication skills to elicit key information 
from patients and to explain and promote the pharmaceutical care concept to patients and other health 
care providers. Documentation systems provide a systemic review of the patients’ health status and drug 
therapy and help pharmacists to provide optimal care of their patients. 
 
III] Resource-Related Constraints  
 
Lack of time to provide pharmaceutical care has been reported by some pharmacists. In reality, 
pharmacists lack time due to the fact that they focus on the wrong activity. A certain amount of time 
could be routinely scheduled for patient care activities, even if it is just a fraction of each day. Several 
studies reported that implementation of pharmaceutical care saves time and increase the profitability of 
the pharmacy. Financial concerns that a lot of money is necessary to redesign the pharmacy, hire more 
personnel, and purchase computer or documentation system were reported as other obstacles. 
Pharmaceutical care is not the physical environment or the computer software, it is a philosophy that 
focuses on interaction with patients, pharmacists can plan changes at a minimal cost by employing good 
money management habits to add personnel or documentation system when needed.  
 
IV] System-related Constraints 
 
The most real and difficult obstacle to be overcome is reimbursement. It will be financially unfeasible for 
most, if not all pharmacists to provide pharmaceutical care over long term without some type of payment. 
Other obstacle is the reluctance of some patients to spend additional time with the pharmacist because 
they are unfamiliar with the pharmacist’s expertise, in addition they believe that pharmacists are invading 
their physician’s terrority and they do not want to anger their physician. The key reason that why patients 
do not demand pharmaceutical care is that they do not understand the concept. Thus, pharmacists need to 
launch a major public relations and education campaign to change the expectations of patients and create 
a demand. A temporary obstacle to the implementation of pharmaceutical care is that not all health care 
providers will appreciate pharmacists as patient care providers and see no value in pharmaceutical care. 
Pharmacists must demonstrate their willingness to be responsible for the patient’s drug therapy and must 
develop close working collaboration with other health care professionals and provide well-thought 
rational drug therapy recommendations to physicians. The acceptance of pharmaceutical care by patients, 
physicians and administrators will be hard due to the lack of research proving its value to society. 
Practitioners, administrators and schools of pharmacy need to coordinate their activities to report research 
outcomes that provide evidence. 
 
 
V] Academic and Educational Obstacles 
 
Faculties of pharmacy must examine their undergraduate curriculum closely, and gain an understanding 
of pharmaceutical care, as it exists today, as well as its evolvement in the future. This understanding will 
allow the faculties to show students how pharmaceutical care can fit into the pharmacy practice as a 
whole. The movement to a student-centered curriculum with emphasis on small group discussions, 
problem solving activities, patient cases and problem-based learning techniques will help students grasp 
pharmaceutical care concepts. Students must interact with patients and other health care professionals 
earlier in their training to increase their understanding of the health care system and improve their skills 
and attitudes. 
 
Many pharmacy students who have become aware of pharmaceutical care express disappointment about 
the lack of experts to follow in providing this care in practice; fortunately this is a temporary obstacle. 
Faculties of pharmacy can help in rectifying this problem through supporting innovative practitioners who 
provide direction and input to the faculties and develop mentoring relationships with students.  
 
١٫٣٫٣  Evaluation of the Pharmaceutical Care Services  
 
Numerous studies have demonstrated that pharmaceutical care services have a significant impact on the 
health care management and health care expenses in the long-term. Pharmacists prevented many drug 
related problems such as hospitalizations, adverse drug events and deaths. Clinical pharmacy services that 
are provided in both hospital and community pharmacies include dosage adjustments for patients with 
certain health conditions, dosage conversion form intravenous route to oral route, patient counseling, 
development of care plans, monitoring drug therapy, making rounds on medical units, giving vaccines 
and providing smoking cessation programs (Schumock et al., ١٩٩٩).  
 
Over the years, many drug related problems have resulted in a decrease in patients’ quality of life, an 
increase in health care costs, and an increase in mortality rates. The annual costs for drug related illness 
and deaths in the United States of America was estimated to be $٧٦٫٦ billion dollars (Johnson and 
Bootman, ١٩٩٧). Several studies reported that pharmacists practicing pharmaceutical care have prevented 
or resolved drug related problems, reduced the inappropriate prescribing, enhanced the management of 
the disease, and improved the medication compliance and patients’ knowledge, and reduced the total 
medical cost for each patient without adversely affecting health-related quality in patients. (Watanabe et 
al.,  ١٩٩٨; Smythe et al., ١٩٩٨; Taylor et al., ١٩٩٨; Asheville project, ١٩٩٨; Munore et al., ١٩٩٧; Cipolle 
et al., ١٩٩٨).  
١٫٤  Asthma in Sudan 
 
There is a lack of information about the prevalence of asthma in Sudan, table ٢ shows the available 
statistical data as obtained from the Ministry of Health. Studies about asthma are very few in Sudan, in 
١٩٩٦, Elhag and Omer carried out a study about the prevalence of nocturnal cough and its relation to 
asthma in Sudanese school children. Their results showed a high prevalence rate of nocturnal cough in 
school children, which was highly suggestive of asthma, and they were likely to benefit from asthma drug 
therapy. 
 
Table ١٫٢: Prevalence of Asthma as provided by Ministry of Health 
 
Year Cases Death Percentage of death 
     ١٩٩٨ ٤٠١١ ٤٠ ٠٫٩ 
     ١٩٩٩ ٢٧٧٢ ٦٩ ٢٫٤ 
     ٢٠٠٠ ٤٧٨٤ ٢٠٦ ٤٫٣ 
     ٢٠٠١ ٧٣١٩ ٦٨ ١ 
 
 
The urban and rural differences in asthma symptoms among ١٤-١٩ years old students was studied by 
Abuobeida (٢٠٠١). The study revealed that the prevalence of asthma and wheeze were significantly 
higher in urban than in rural areas and the severity of asthma increased with urbanization, it also showed 
the under diagnosis and under treatment of the disease. 
 
Asthma is increasing all over the world particularly in developing countries such as Sudan. Major 
questions for researchers will arise such as is there an evidence that asthma is being appropriately treated 
in Sudan; is there evidence that asthma is treated according to the national or international guidelines; is 
there evidence that the asthmatic patients are provided with the best health care, is the contribution of the 
pharmacists in asthmatic patients care with other health team members will improve their outcomes. From 
these questions the objectives of this research work were developed. 
 
 
 
 
 
 
 
 
١٫٥ Objectives of the Present study 
 
It was reported that patients with asthma were associated with a high frequency of drug related morbidity 
(National Heart, Lung and Blood Institutes of Health, ١٩٩٢). Prescribing practices at ٢٠ health centers 
and two teaching hospitals in Khartoum state were described as poor and illogical (Awad, ١٩٩٩; Himad, 
٢٠٠٤). There are no reported studies that have evaluated the quality of prescribing practices for asthmatic 
patients in Sudan. This study was designed to investigate the current prescribing practices for patients 
with chronic asthma and acute attacks of asthma. 
  
The overall research hypothesis was that implementing pharmaceutical care services for asthmatic 
patients could improve their health status, and cost-effectiveness of their drug therapy. This hypothesis 
was tested through implementation and evaluation of the pharmaceutical care services in a one year 
controlled study. 
 
The objectives of the present study include: - 
 
١. Investigation of the current prescribing practices for the treatment of chronic asthma 
 
٢. Investigation of the current prescribing practices for the management of acute attacks of asthma. 
 
٣. Implementation and evaluation of the impact of pharmaceutical care service in Sudanese asthmatic 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter ٢ 
 
 
 
 
 
  
Investigation of the Current 
Prescribing Practices for the 
Treatment of Chronic Asthma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ٢٫١ Introduction 
 
٢٫١٫١ Background to the Prescribing Practices  
 
 The prescribing of medicines is an integral part of the health service; without its hazards it is relatively 
safe, effective and inexpensive mode of therapy. Drug utilization focuses mainly on the quantity and 
availability rather than the quality of prescribing. Good quality of prescribing must be a part of indicators 
for assessing the quality of patients’ care (Williams, ٢٠٠٢). 
 
Prescribing errors on general practice prescriptions are common. Error is defined as “ the failure of a 
planned action to be completed as intended or the use of a wrong plan to achieve an aim”. Errors can 
occur in all the stages of the care process, from diagnosis to drug administration, including incorrect 
prescribing, inadequate information given by the prescriber or the pharmacist to the patient, and incorrect 
use of medicines by the patient. All can cause suffering of the patient and increasing the cost of care. 
Careful checking of the prescriptions by the pharmacist reduce patients’ harm (Nadeem  et al., ٢٠٠١). 
 
A study about prescriptions errors in three Sudanese paediatric hospitals (Omdurman, Ahmed Gasim and 
Albuluk) revealed that the percentage of prescriptions errors was too high indicating poor prescribing 
practices. (Khalafalla et al., ٢٠٠٣). In ٢٠٠١, Awad et al reported poor prescribing practices in ٢٠ health 
centers at Khartoum-state.  
 
These results showed the need for an effective and continuous in-service training of prescribers and 
dispensers. The study recommended the introduction of the clinical pharmacy services in all hospitals.The 
persistence of uncontrolled asthma remains a serious problem world-wide, the major factors that 
contribute to this include the inappropriate prescribing that leads to ineffective management, in addition 
to patient non-compliance, and lack of knowledge and skills on the parts of patients and health care 
professionals (Larsen and Hansen, ١٩٨٥; Synder et al., ١٩٨٧; WHO, ١٩٩٥; Herborg et al., ٢٠٠١).  
 
The possible differences between the high and low quality of asthma prescribing practices in the Bradford 
Health Authority was investigated and researchers suggested the use of the ratio of preventors to 
bronchodilators (P: B) as an indicator of asthma prescribing, they found low quality practices due to the 
with low ratios of P: B and recommended that joint initiatives for disease management of asthma should 
initially focus on these practices with low P: B (Salamzadeh et al., ٢٠٠٠). In ٢٠٠٢, Williams used the 
ratio of inhaled corticosteroids to bronchodilators as one of the prescribing indicators for asthma. 
 
 
 ٢٫١٫٢ Treatment of Chronic Asthma 
 
Table ٢٫١shows the stepwise guidelines for the management of chronic asthma in adults and children as 
recommended by The British Thoracic Society in ١٩٩٧. Inhalation is the preferable route of 
administration as it allows the drugs to be delivered directly to the airways thus reducing the required 
dose and side effects. The choice of an inhalation device and assessment of patient’s inhaler technique are 
important steps in treatment of asthma.  Infrequent attacks are managed when occur but the more frequent 
attacks require preventive therapy and stepwise progression in treatment is always preferable.  
 
The treatment should be started at most appropriate step to the initial severity. The rescue course of 
prednisolone may be required at any step to achieve early control of the condition and then the treatment 
should be reduced.  The treatment should be reviewed every ٣-٦ months; stepwise reduction may possible 
if the control is achieved. If the treatment is started at step ٤ or ٥ or contained corticosteroids tablets, the 
reduction may be after short interval. In others a ١-٣ month or longer time of stability is required before 
the therapy is stepped down slowly (BNF, ٢٠٠٢). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table [٢٫١]: Guidelines for the management of chronic asthma in adults and children as 
recommended by The British Thoracic Society in ١٩٩٧. 
 
Step Treatment type Recommended drugs and doses 
١ Occasional use of relief 
bronchodilators 
Inhaled short acting β٢ agonists as required, if needed more than once 
daily, move to step ٢ 
٢ Regular inhaled anti-inflammatory 
agents [preventer therapy] 
Inhaled short acting β٢ agonists as required plus inhaled standard-dose 
steroid* 
Alternatively use cromoglycate or nedocromil sodium, but if control is 
not achieved start inhaled steroids  
٣ High dose inhaled steroids or 
standard- dose inhaled steroids plus 
long acting inhaled β٢ agonists 
bronchodilator 
Inhaled short acting β٢ agonists as required plus inhaled high-dose 
steroids† (via a large volume spacer) 
In patients who experience side effects with high dose steroids the 
following can be added to standard- dose inhaled steroids*                      
i] Salmeterol ٥٠µg twice daily or formoterol ١٢ µg daily in those >١٨
years 
or 
ii] Sustained release theophylline 
or 
iii] Cromoglycate or Nedocromil may also be tried    
٤ High dose inhaled steroids and 
regular bronchodilators 
Inhaled short acting β٢ agonists as required with inhaled high-dose 
steroid† (via a large volume spacer) plus a sequential therapeutic trial 
of one or more of the following: 
inhaled long acting β٢ agonists, sustained release of theophylline 
inhaled ipratropium or oxitropium, long acting β٢ agonists tablets 
high dose inhaled bronchodilators, cromoglycate or nedocromil 
 
٥ Regular Steroid Tablets Inhaled short acting β٢ agonists as required with inhaled high-dose 
steroid† (via a large volume spacer) and one or more long-acting 
bronchodilators plus regular prednisolone tablets as a single daily dose.
* Standard--dose inhaled corticosteroid (based on delivery via a metered dose inhaler [MDI]) = budesonide or 
beclomethasone١٠٠-٤٠٠ µg  twice daily or fluticasone ٥٠-٢٠٠µg  twice daily 
† High-dose inhaled corticosteroid (based on delivery via MDI) = budesonide or beclomethasone ٨٠٠- 
٢٠٠٠ µg  daily or fluticasone ٤٠٠-١٠٠٠ µg daily 
 
٢٫٢ Method 
 
٢٫٢ ١ Study Area:  
 
Shaab teaching hospital is one of the major teaching hospitals in Sudan, it is located in Khartoum state. 
The hospital medical units are neurology, neurosurgery, chest and cardiology, and cardio thoracic 
Surgery. It contains about ١٠ wards, ٢ intensive care units, ٢ intermediate care units, ١ intensive coronary 
care unit, ١ intermediate coronary care unit, ١ asthma care unit and ١ emergency department for both 
chest and cardiology. It also contains The National Center of Cardiology and the National Center of 
Neurosurgery. The hospital contains about ١٦٠ beds and served approximately ٤٨٠ inpatients per month. 
 
This study was conducted in one of the largest teaching hospitals in Sudan due to the important role of the 
teaching hospitals in teaching and training of our health care providers and the fact that they also provide 
health services to a large number of the population, there is a need for research work to assess the drug 
use patterns in the teaching hospitals in Sudan. 
 
٢٫٢٫٢ Inclusion and exclusion criteria 
 
Patients’ encounters to be included were chronic asthmatics encounters prescribed for asthmatic patients 
attending the out patient clinic. Samples were taken from adults. The in-patients prescriptions were 
excluded.  
 
٢٫٢٫٣ Study Design and Sampling Strategy 
 
This is a descriptive, quantitative and cross-sectional hospital based survey to investigate the prescribing 
practices for the treatment of chronic asthma. The sample size was determined according to the WHO 
recommendation that a minimum of ١٠٠ samples per facility should be collected for the assessment of 
prescribing practices. Thus, a sample size of ١٢٥ prescriptions was collected randomly. 
Systematic sampling was used for data collection 
١. Sampling interval  =      Total number of prescriptions collected 
                                        Number of prescriptions to be included in the sample  
                                 ٢٠٠/١٢٥ =  ١٫٦  
٢. The random number had been chosen from the standard random table was multiplied by the 
sampling interval; the result was rounded up to get the number of first prescription. 
١٫٦ x ٠٫١٨٣ = ٠٫٢٩, which was rounded up to ١, so the first prescription was chosen for the sample, then 
other prescriptions selected by adding the sampling interval to the previous result, the first result was ٠٫٢٩ 
then the next prescriptions selected were as follows 
 
٠٫٢٩      ---   ١ 
٠٫٢٩ + ١٫٦ = ١٫٨٩     prescription number ٢ 
١٫٨٩ + ١٫٦ = ٣٫٤٩     prescription number ٤ 
٣٫٤٩ + ١٫٦ = ٥٫٠٩     prescription number ٥ 
٥٫٠٩ + ١٫٦ = ٦٫٦٩     prescription number ٧ 
٦٫٦٩ + ١٫٦ = ٨٫٢٩     prescription number ٩  and so on 
 
Data Collection ٢٫٢٫٤  
 
١٢٥ prescriptions for the treatment of chronic asthma were collected prospectively due to inadequate   
sources of retrospective data. Data was collected during the period from February to October ٢٠٠٣ to 
include different days and times, to ensure that data is comprehensive (representative data) and to 
enhance its validity and reliability. 
 
The indicators that were used to assess the prescribing practices for the treatment of chronic asthma 
include   
 
i] The percentage of prescription including all the basic necessary information (date, name of patient, age 
of patient, diagnosis, strength of drug, directions for use, quantity of drug to be dispensed, and signature 
of the prescriber). 
         ii] Number of drugs prescribed per prescription. 
        iii] Percentage of prescriptions with drug-drug Interactions. 
        iv] Percentage of inhaled steroids prescribed. 
         v] Percentage of oral steroids   prescribed. 
        vi] Percentage of inhaled bronchodilators prescribed 
       vii] Percentage of oral bronchodilators prescribed 
       viii] Percentage of antibiotics prescribed 
 
٢٫٢٫٥ Data Analysis 
 
Data were entered and analyzed using templates created in Microsoft Excel version ٢٠٠٠.  
Results are presented in tables.  
 
٢٫٢. ٦. Pilot test: 
               
 A pilot study of data collection, data entry and analysis was conducted on ١٠ prescriptions prior to the 
study to ensure validity and reliability of the methodology of data collection and the results of the study.  
Prescriptions used in the pilot test were excluded from the study sample.  
٢٫٣ Results and Discussion 
 
Table ٢٫٢ shows the results of evaluating the issued prescription for the inclusion of the basic necessary 
information. The results revealed that all collected prescriptions were without age and diagnosis. The 
diagnosis is necessary to ensure the appropriate selection of drug therapy. The date was not written in 
٨٣٫٧٪ of them. The date on which the prescription was issued is required to confirm the period of validity 
of the prescription, moreover, it is very crucial as a lot of Sudanese patients used to refill their 
prescriptions for long time without checking with their physicians particularly those with chronic diseases 
such as asthma in which the monitoring of the patients condition and stepping of treatment are very 
important.  
 
The name of the medicine was not clearly written due to bad handwriting or spelling mistakes in ٣٢٪ of 
the prescriptions. In, ٢٠٠١,Nadeem et al reported that hand written prescriptions lead to a higher rate of 
prescribing errors. The strength of the drug and the quantity to be dispensed were not shown in ٦٨٪ and 
٨٠٫٨٪ of the prescriptions, respectively. The dosage form and the directions for use were not written in 
٣٫٢٪ and ٤٪ of the prescriptions, respectively. The strength of the drug specifies the concentration of the 
dosage form, the quantity of the drug to be dispensed verifies the duration of treatment and the directions 
to use the drug identify how often to be taken and any specific instructions and warnings. The missing of 
any one of these dosing specifications may lead to irrational utilization such as their use in subdoses, 
overdoses and for inadequate duration. Prescribers did not sign ٤١٫٦ % of the prescriptions, and in those, 
which were, signed ٧٨٫١٪ of them were with unclear signature. None of the prescriptions shows clearly 
the doctor’s name and his/her qualification (house officer, medical officer, registrar or consultant). 
 
Table ٢٫٢: Evaluation of the prescriptions for their inclusion of the basic necessary information 
 
Basic Necessary Information Number of Prescriptions Percentage of Prescriptions 
Date ٢١ ١٦٫٦ 
Age ٠ ٠ 
Diagnosis ٠ ٠ 
Clear handwriting of drugs ٨٥ ٦٨ 
Quantity to be dispensed ١٥ ٣٢ 
Dosage form of the drug ١٢١ ٩٦٫٨ 
Directions to Use of the drug ١٢٠ ٩٦ 
Signature of the prescriber ٧٣ ٥٨٫٤ 
 
The present results revealed that the minimum information required to be in the prescription was missed 
in many of the prescriptions. There is no global standard for prescription; every country has its own 
standards for the minimum information required for a prescription. Prescription should be legible and 
indicate accurate diagnosis and what should be given; additionally if the prescription includes the 
following information, not much can be a failure: date on which the prescription was written, name of the 
patient, Strength of the drug, quantity of the drug to be dispensed to the patient, direction to use (should 
contain the amount of drug to be taken, the frequency and the route of administration) and signature of the 
prescriber. Every prescription should indicate the above listed basic data (De Vries et al, ١٩٩٤). 
 
Table ٢٫٣ shows the results of evaluating the prescribing indicators, in ٦٩٫٦٪ of the prescriptions the 
number of drugs prescribed were in the range of ١-٢ drugs / prescription, while three and four drugs were 
prescribed in ٢٤٪ and ٦٫٤٪ of the prescriptions, respectively. The most favorable average number of 
drugs per encounter should be less than ٢ (Hogerzeil, ٢٠٠٢).  It was reported that the drugs related 
problems are directly proportional to the number of drugs per prescription but this may not be the rule in 
asthma, as many patients need more than one drug for controlling their disease. However this study 
identified the favorable number of drugs prescribed per encounter, the reason behind this may be possibly 
related to the patient's inability to meet the drug expenses and the fact the prescribers do consider the 
economical status of the patients, or may be due to a good selection of drug therapy according to accurate 
diagnosis and the patient current health status but not symptomatic treatment.  
 
Potential drug -drug interactions through prescribing of erythromycin and theophylline were identified in 
١٫٦٪ (٢) of the prescriptions. Drug disease interactions were ٠٪. Inhaled steroids and inhaled plus oral 
steroids were prescribed for ٢٤٫٨٪ and ٤٫٨٪ of the patients, respectively. Oral steroids were prescribed 
for ٣٢٪ of the patients. The dose of inhaled steroids was written appropriately in ١٣٫٥٪ of the 
prescriptions. Oral steroids dose was inappropriate in ١٥٫٢٪ of the prescriptions. Theophylline was 
prescribed for ١٨٫٤٪ of the patients. Oral, inhaled and oral plus inhaled β٢-agonists were prescribed for 
١٦٪, ٢٨٫٨٪, and ١٫٦٪ of the patients respectively. The specific dose was not written in any of the 
prescribed inhaled β٢-agonists while ٥٤٫٥٪of the oral β٢-agonists doses were inappropriate. . The ratio of 
inhaled corticosteroids to bronchodilators in asthmatic patients may be used as prescribing indicator for 
quality of prescribing (Williams, ٢٠٠٢). Salamzadeh et al (٢٠٠٠) studied the prescribing practice in 
asthma and they reported that practices of low preventor to bronchodilators prescribing ratio were 
practices of low quality. In this study, the ratio of using inhaled steroids to bronchodilators was ١: ٢٫٦ 
[٢٤٫٨٪: ٦٤٫٨٪] indicating prescribing practices of low quality. 
 
Antibiotics were prescribed in ٣٥٫٢٪ of the prescriptions, ٧٧٫٢٪ of the prescribed antibiotics was 
erythromycin, others prescribed antibiotics include penicillins, cephalosporins and azithromycin. This 
illustrates that the antibiotic of choice for asthmatics patients with infections is erythromycin, due to the 
fact that diagnosis was not indicated in the prescription, it would not be possible to judge on the 
appropriateness of erythromycin selection. The overall resistance of micro-organisms to antibiotics was 
reported by Sid Ahmed (١٩٩٥) to be high and that the selection of drug resistance has been associated 
with the increase in the irrational use of antibiotics in Sudan. A study conducted in health centers in 
Khartoum state revealed that the percentage of encounters prescribed with an antibiotic was ٧٣٪ with an 
inappropriate dose and duration of therapy for children and adults of ٧٧٪ and ٥٨٪, respectively, ٦٠ % of 
the prescribed antibiotics was amoxicillin and ٨٪ erythromycin (Awad et al., ٢٠٠١). A recent study in 
٢٠٠٤ reported that the average percentage of antibiotic prescribed in Omdurman and Khartoum teaching 
hospitals was ٦٥٪ (Himad, ٢٠٠٤). The antibiotic prescribing in Sudan is very high when compared to that 
recommended by Hogerzeil, ٢٠٠٢ to be less than ٣٠٪. The inappropriate increase in the prescribing of the 
antibiotics would favour the development of antibiotic resistance, increase in the incidence of serious side 
effects together with waste of resources leading to increased costs                                                  
 
Factors underlying the described current prescribing practices were unknown, In ١٩٩٩, Awad et 
al, reported that the major factors that influenced prescribing practices in the health centers were the lack 
of pharmacotherapeutic knowledge and the patients’ demand. 
 
Table ٢٫٣ Results of the Prescribing Indicators  
 
Indicator Number of Prescriptions 
Steroids 
• Inhaled Steroid 
• Oral steroids 
• Inhaled Steroid + oral steroids 
 
 
 
٣١ 
٤٠ 
٦ 
Theophylline ٢٣ 
B٢- agonists 
• Inhaled β٢-agonist 
• Oral β٢-agonist 
• Inhaled+ Oral β٢-agonist 
 
 
٣٦ 
٢٠ 
٢ 
Antibiotics 
• Erythromycin 
• Penicillins 
• Cephalosporins 
• Azithromycin 
 
٤٤ 
٣٤ 
٥ 
٣ 
٢ 
 
 
 
٢٫٤ Conclusion and Recommendations 
 
The prescribing practices at the teaching hospitals are expected to be of good quality, since they provide a 
significant role in teaching and training of health care providers and the fact that they also provide health 
services to a large number of the population. In reality, many studies world-wide indicated that some of 
their prescribing practices are of poor quality. The results of this study pointed out the common 
prescribing errors in the prescribing practices for the treatment of chronic asthma.  
 
Qualitative methods should be designed and implemented to identify the causes underlying the problems 
identified by this study. Interventional methods such as continuing medical education, establishment of 
updated national guideline for management of asthma may be effective in improving the prescribing 
practices.  
 
Continuous collaboration between the pharmacist and the physicians should be established since it is 
quite necessary for providing health care of better quality to the patient. The prescription should contain 
all the necessary basic data that will enable the pharmacist to participate in the decision-making of its 
appropriateness. The well-trained pharmacists continue to have important role in checking prescriptions 
and encouraging prescribers to good prescribing practices for improving quality of care. Good 
communication between health care professionals should be encouraged since it is of great value in 
improving the quality of prescribing and patients’ care. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter ٣ 
 
 
 
 
 
 
 
Investigation of the Current 
Prescribing Practices for the 
Management of Acute Attacks of 
Asthma 
 
 
 
 
 
 
 
 
٣٫١ Introduction 
 
٣٫١٫١ Clinical Features of Acute Attacks of Asthma  
 
Acute exacerbations of asthma may be presented as uncontrolled asthma with the following clinical 
features: normal speech, pulse less than ١١٠ beats/minute, Respiratory rate less than ٢٥ breaths/minute 
and a peak expiratory flow (PEF) of greater than ٥٠٪ of predicted or best value. It may be easily managed 
in the community by general practitioners through the use of nebulized β٢-agonist (salbutamol ٥mg or 
terbutaline١٠mg) then the response is monitored after ١٥-٣٠ minutes of nebulization, if PEF is ٥٠-٧٥٪ of 
predicted or best value, the patient is given oral prednisolone and usual treatment stepped up, but if PEF 
>٧٥٪ of predicted or best value then the usual treatment should be stepped up. Patient then should be 
monitored for symptoms and provided with self-management plan (British Thoracic Society, ١٩٩٧). 
 
Acute severe asthma requires prompt referral to hospital and its management depends on the severity of 
the attack and its response to treatment .The patient’ past history and present drug therapy use are 
important to be considered. The aims of treatment are to prevent any deterioration in the patient’s 
condition and to fasten recovery .The clinical features of acute severe asthma include inability to 
complete sentences in one breath during speech, pulse >١١٠ beats/minute, respirations >٢٥ 
breaths/minute and PEF ≤ ٥٠٪ of predicted or best. Clinical features of life threatening asthma include 
silent chest, cyanosis or feeble respiratory effort, bradycardia or hypotension, and exhaustion, confusion 
or coma. PEF <٣٣٪ of predicted or best. Patients with severe or life threatening attacks may not be 
distressed and may not have all above mentioned abnormalities, the presence of any should alert the 
physician (Gibbs and Small, ٢٠٠٣).  
 
٣٫١٫٢ Guideline for the Management of Acute Severe Asthma in Adults (British Thoracic Society, 
١٩٩٧) 
 
I] Immediate Treatment 
• Oxygen ٤٠-٦٠٪ 
• Nebulized salbutamol ٥mg or terbutaline ١٠ mg via an oxygen driven nebuliser.  
•  Oral prednisolone (٣٠-٦٠mg) or intravenous hydrocortisone ٢٠٠mg or both if very ill and the 
then the response monitored ١٥-٣٠ minutes after nebulization. 
• No sedatives of any kind 
• Chest radiograph to exclude pneumothorax 
 
 
 
IF LIFE THREATENING FEATURES ARE PRESENT 
• Add Ipratropium (٠٫٥ mg) to the nebulized β٢ agonist. 
• Give intravenous aminophylline (٢٥٠mg) over ٢٠ minutes  [Do not give bolus aminophylline to 
patients already taking oral theophyllines] OR salbutamol or terbutaline ٢٥٠ µg over ١٠ minutes.  
 
II] Subsequent Management 
 
IF PATIENT IS IMPROVING CONTINUE: 
• ٤٠-٦٠ % oxygen 
• Prednisolone ٣٠-٦٠ mg daily OR intravenous hydrocortisone ٢٠٠ mg ٦ hourly 
• Nebulized β٢ agonist ٤ hourly 
 
IF PATIENT IS NOT IMPROVING AFTER ١٥-٣٠ MINUTES: 
• Continue oxygen and steroids 
• Give nebulized β٢ agonist more frequently, up to every ١٥-٣٠ minutes 
• Add ipratropium ٠٫٥ mg to nebulizer and repeat every ٦ hourly until patient is improving 
 
IF PATIENT IS STILL NOT IMPROVING GIVE: 
• Aminophylline infusion (small patient ٧٥٠ mg/٢٤ hr, large patient ١٥٠٠mg/٢٤hr); monitor blood 
concentrations if it is continued over ٢٤ hr 
• Salbutamol or terbutaline infusion as an alternative to aminophylline infusion. 
 
III] Monitoring Treatment 
• Repeat measurement of PEF ١٥-٣٠ minutes after starting treatment 
• Oximetery: maintain SaO٢  > ٩٢٪  
• Repeat arterial blood gas measurements [Measure them initially if SaO٢  < ٩٢٪ or patient has any 
life threatening features] 
• Chart PEF before and after giving inhaled β٢ agonists and at least ٤ times daily throughout 
hospital stay. 
• Transfer patient to ICU if there is deteriorating PEF, worsening or persisting hypoxia, or 
hypercapneia, exhaustion, feeble respirations, confusion, coma or respiratory arrest. 
 
IV] When discharged from hospitals, patients should have: 
• Been on discharge medication for ٢٤ hr and have had inhaler technique checked and recorded. 
• PEF > ٧٥٪ of predicted or best and PEF diurinal variation < ٢٥٪, unless discharge is agreed with 
respiratory physician. 
• Treatment with oral and inhaled steroids in addition to bronchodilators. 
• Own PEF meter and written self-management plan 
• GP follow up arranged within one week 
• Follow up appointment in respiratory clinic within ٤ weeks 
• Also determine reason (s) for exacerbation and admission 
• Send details of admission, discharge and potential best PEF to GP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
٣٫٢ Method 
        
٣٫٢ ١ Study Area:  
 
The study was conducted in Shaab teaching hospital from March to April ٢٠٠٣.More details about the 
hospital were given in chapter ٢. 
 
٣٫٢٫٢ Inclusion and Exclusion criteria 
 
Patients’ encounters to be included were encounters prescribed for asthmatic patients with acute attacks 
attending the emergency department. Samples were taken from adult patients.  
 
٣٫٢٫٣ Study Design and Sampling Strategy 
 
This is a descriptive quantitative cross-sectional hospital based survey to investigate the management of 
acute exacerbations of asthma. The sample size was determined according to the WHO recommendation 
that a minimum of ١٠٠ samples per facility should be collected. Thus, sample sizes of ٢٥٠ admission 
sheets were collected randomly. 
Systematic sampling was used for data collection 
١. Sampling interval  =      Total number of admission sheets collected 
                                        Number of admission sheets to be included in the sample  
                                  ١٠٠٠/٢٥٠ =  ٤  
 
٢. The random number had been chosen from the standard random table was multiplied by the sampling 
interval; the result was rounded up to get the number of first admission sheet. 
٤ x ٠٫١٨٣ = ٠٫٧٣, which was rounded up to ١, so the first admission sheet was chosen for the sample, 
then other admission sheets selected by adding the sampling interval to the previous result, the first result 
was ٠٫٧٣ then the next admission sheets selected were as follows 
 
٠٫٧٣      ---   ١ 
٠٫٧٣ + ٤ = ٤٫٧٣     admission sheet number ٥ 
٤٫٧٣ + ٤ = ٨٫٧٣     admission sheet number ٩ 
٨٫٧٣ + ٤ = ١٢٫٧٣     admission sheet number ١٣ 
١٢٫٧٣ + ٤ = ١٦٫٧٣     admission sheet number ١٧ 
١٦٫٧٣ + ٤ = ٢٠٫٧٣     admission sheet number ٢١ and so on 
 
 
 
٣٫٢٫٤ Data Collection 
 
٢٥٠ admission sheets for the treatment of acute attacks of asthma were collected retrospectively. The data 
collected include different days and times, to ensure that data is comprehensive (representative data) and 
to enhance its validity and reliability. 
 
The indicators that were used to asses the prescribing practices for the treatment of acute asthma include   
i] Evaluation of admission sheets for the following basic necessary information (date, name of patient, 
age of patient, and residence of the patient). 
ii] Evaluation of admission sheets for reporting of the Vital signs for assessment of acute attacks of 
asthma. 
iii] Evaluation of the current drug therapy of acute attacks of asthma in accordance with the BTS and 
national guidelines. 
 
٣٫٢٫٥ Data Analysis 
 
Data was entered and analyzed using templates created in Microsoft Excel version ٢٠٠٠. 
Data is presented as Figures.  
 
٣٫٢. ٦ Pilot test: 
     
 A pilot study of data collection, entry and analysis was conducted on ١٥ admission sheets, it was carried 
out prior to the study to ensure validity and reliability of the data collection and the results of the study.  
Admission sheets used in the pilot test were excluded from the study sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
٣٫٣ Results and Discussion 
 
The results of assessing the admission sheets for its inclusion of the demographic data revealed that ٥٦٪ 
of the admitted patients were males and ٤٤٪ were females, the majority of the patients (٤٤٫٨٪) were 
between the age group of ٢٠-٤٠ years old (figure ٣٫١), in ١٣٫٢٪ of the admission sheets the ages of the 
patients were not written. Patients’ residence was documented in ٥٤٪ of the patients’ admission sheets; 
the majority of patients were from Khartoum (figure ٣٫٢). The demographic data is crucial in the 
management of patients’ diseases as the prescribing of drugs may be influenced by the patients’ age and 
sex in addition to their importance in the documentation of the disease prevalence. Also, the geographical 
distribution is an indicator for the detection of risk factors associated with asthma in specific areas such as 
industrial areas or farms. As it was shown in the results that the age and the residence were not written in 
١٣٫٢٪ and ٤٦٪ of the collected sample, respectively. Such a lack of necessary data may contribute to the 
non-existence of actual data for the epidemiology of asthma in Sudan.  
 
Figure ٣٫١: Distribution of Patients by Age Groups 
 
 
Figure ٣٫٢: Distribution of Patients by Residence 
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The results of investigating the admission sheets for the recording of the pulse (P), respiratory rate (RR), 
blood pressure (BP) measurements have shown that none of the three were recorded in ٣٢٫٤٪ of the total 
collected sample, all of them were recorded only in ٦٠ admission sheets (figure ٣٫٣). Peak expiratory 
flow rate (PEFR) measurement was not recorded in all collected sheets. The full medical history was 
written in ٤٪ of the sheets. The corner stone in the management of acute exacerbations of asthma is the 
assessment of the severity of the attack, the main signs (P and RR) and PEFR should be initially assessed 
and followed up after starting the treatment as recommended by many international guidelines such as the 
British, Scottish and Egyptian guidelines. The Sudanese manual of asthma stated only that P and PEFR 
should be assessed .The results of this study showed the lack of reporting these signs in the admission 
sheets, but it is not known whether they were assessed but not written on the sheet or not being assessed 
initially. However, if they were done they must be written so as to evaluate their improvement or 
deterioration during treatment. It was clear from the present results that none of the patients was assessed 
by PEFR and this may be due to the fact that there are no peak flow meters for use in the casualty.  It was 
found that the full medical history was written only in the admission sheets of ١٠ patients. Appreciation 
of the patients’ past medical history and present treatment is very important in the management of acute 
asthma (Gibbs and Portlock, ٢٠٠١). 
 
Figure ٣٫٣: Percentage of admission Sheets according to Reporting of the Vital signs for 
Assessment of Acute Attacks of Asthma  
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The results of evaluating the appropriateness of the management of acute attacks of asthma as written in 
the admission sheets revealed that oxygen was indicated in ٣٦ (١٤٫٤٪) sheets without stating any 
concentration that should be administered to the patient.  It was stated in the BTS guidelines that patients 
with acute attacks should receive ٤٠-٦٠٪ oxygen, and in the Sudanese asthma manual should receive 
P: Pulse 
RR: Respiratory Rate 
BP: Blood Pressure 
NO: Percentage of 
admission sheets with no 
vital signs written on them 
 ٦ litres /minute. Different dosage regimens of nebulized salbutamol with different frequencies of 
administrations were found in the total collected sample Figure ٣٫٤ clearly illustrates the high incidence 
of deviation from the recommended dose and frequency of administration as recommended by BTS 
guidelines (table ٣٫١٫٢). The Sudanese manual stated that ٥mg of nebulized salbutamol should be given 
every ٢٠ minutes in the first hour followed by a dose every hour till complete response. It was found that 
the majority of patients did not receive the starting recommended dose ٥ mg. The present results indicated 
the irrational prescribing of nebulized salbutamol inappropriate dose and frequency of administration, 
which may lead to increase in the incidence of adverse drug reactions, waste of resources and 
inappropriate management of the acute attacks of asthma. 
 
 
Figure ٣٫٤: Percentage of admission sheets with the reported dosage and frequency of 
administration of nebulized salbutamol  
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Regarding the prescribing of intravenous aminophylline, it was found in ١٥  (٦٪) sheets to be given as a 
single dose of ٢٥٠mg and in ٣ (١٫٢٪) sheets to be administered as ٢٥٠-mg/٨ hr. In the medical history of 
present drug therapy, it was not shown whether these patients were already taking oral theophylline or 
not. This indicates the infrequent use of intravenous aminophylline, which should be the last line of 
treatment after the failure of salbutamol or terbutaline infusion due to the fact that it is a drug of narrow 
therapeutic window, which requires therapeutic drug monitoring to prevent its toxicity.  
 
Figure ٣٫٥ shows the percentage of admission sheets with the reported dosage and frequency of 
administration of hydrocortisone. The steroids were prescribed in ٩٣٫٢٪ of the admission sheets. 
Inadequate dose of ١٠٠ mg intravenous (IV) hydrocortisone were found in ٢٥٫٤ % of the sheets. The BTS 
guidelines stated that the patient should receive ٢٠٠mg IV hydrocortisone or ٣٠-٦٠mg prednisolone and 
Sudan manual recommended ٢٠٠mg ٤ hourly, thus ١٠٠ mg is less than the recommended dosage. Oral 
prednisolone was prescribed in ٥٫٦٪ of the collected sample with a dose of ٣٠ mg.  ٦٤٫٤٪ of the patients 
were administered only a single dose of ٢٠٠ mg hydrocortisone not followed by oral prednisolone, this is 
considered inadequate if the patient is very ill.  
 
Figure ٣٫٥:  Percentage of admission sheets with the reported dosage and frequency of 
administration of intravenous hydrocortisone. 
 
10
0m
g-
1 
do
se
10
0m
g 
6 
ho
ur
ly
20
0m
g 
6 
ho
ur
ly
20
0m
g 
th
en
10
0m
g 
6 
ho
ur
ly
N
ot
 g
iv
en
200mg 
1 dose
0
10
20
30
40
50
60
70
Dose and frequency
Pe
rc
en
ta
ge
 
As it is demonstrated form the present results that the management of acute attacks of asthma was not 
following the recommended guidelines in many cases and there was inadequate assessment of the patients 
and the severity of their attacks. This will contribute to the increased patients visits to the emergency 
department and the increased cost of care and poor quality of patient care. The lack of updated national 
guideline for the management of asthma, continued education, supervision and monitoring could be the 
major factors that contributed to that practice. In addition, the lack of equipments as peak flow meters and 
those for the measurement of blood gases, therapeutic drug monitoring could be other contributing factors 
but this should not significantly affect the appropriate assessment and management of asthma to that 
extent. 
 
 
 
٣٫٤ Conclusion and Recommendations 
 
The pattern of prescribing practices for the management of acute attacks of asthma was 
inappropriate indicating the inadequate management of acute exacerbations of asthma.  
 
Well-equipped asthma centers and updated national guideline for the management of asthma 
should be established. Continuing medical education, supervision and monitoring of the practice 
of the prescribers particularly the junior medical staff should be encouraged and implemented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter ٤ 
 
 
 
 
Implementation and Evaluation of 
the Impact of Pharmaceutical Care 
Service in Sudanese Asthmatic 
Patients. 
 
 
 
 
 
 
٤٫١ Introduction 
 
٤٫١٫١ The Asthmatic Patient Care 
 
The corner stone of management of asthma is the correct use of drugs and patient education. Education of 
asthmatic patients include three main steps: 
a] The patient should understand the action of each of the drugs they use. 
b] The appropriate choice of inhalation device(s) should be made and the patient should be educated 
about their correct use. 
c] An individualized self-management plan should be developed for each patient. 
 
Patient counseling will lead to increased patient confidence in ability to self manage asthma; a decrease of 
hospital admission rates and emergency visits. Improving of the patients’ quality of life and increasing in 
his/her compliance may occur as a result of appropriate patient counseling. Specific counseling on drug 
therapy should focus on three areas: drugs that used to relieve symptoms; drugs that used to prevent 
attacks of asthma and drugs given only as reserve treatment for severe attacks (Gibbs and Protlock, 
٢٠٠١). 
 
Pharmacists may contribute in asthma care in different ways: - 
• Educating Patient about asthma medications. 
• Instructing patients about the proper inhalers techniques. 
• Encouraging patients purchasing OTC asthma inhalers or tablets to seek medical care.                                        
• Help patients to use peak flow meters appropriately.                               
• Help patients discharged from the hospital to understand their asthma management plan. 
• Monitor medications use and help to identify patients with poorly controlled asthma to be 
referred to their physician (Gibbs and Protlock, ٢٠٠١).   
 
٤٫١٫٢ The value of pharmaceutical care to the asthmatic patient 
 
Disease specific primary care clinics for chronic diseases, such as asthma provide pharmaceutical care 
through improved multidisciplinary collaboration. There is evidence that hospital and community 
pharmacists have the opportunity to co-operate with each other in a multidisciplinary team, and by doing 
so, they contribute in improving asthma care and preventing hospitalizations (Boyter., et al ٢٠٠٠). 
Cordina et al (٢٠٠١) carried out a community-based pharmaceutical care program for patients with 
asthma in Malta, which had positive impact on vitality of the patients, inhaler technique and peak 
expiratory flow rate. Stergachis et al (٢٠٠٢) reported the non-significant effect of pharmaceutical care 
intervention in improving outcomes of pediatric patients with asthma in the community setting in Western 
Washington State. 
Herborg et al (٢٠٠١) carried out two research projects on improving drug therapy for patients with 
asthma at the level of community pharmacy in Denmark. The first research revealed that therapeutic 
outcomes monitoring by community pharmacist could be effective in improving drug therapy for 
asthmatic patients in primary health care. The second research results showed that if community 
pharmacists, physicians, and patients work together, this will improve prescribing, solve drug related 
problems and improve outcomes for patients with moderate to severe asthma.  
 
In١٩٩٨, Bell et al. reported that the pharmacist-led intervention sessions were shown to improve the 
primary school teachers’ knowledge of asthma, and hence this may be a service, which pharmacists could 
provide within the community setting. Shaw et al (١٩٩٨) showed  that quality of life of asthmatic patients 
could be employed as an outcome measure through pharmaceutical care provision. Pharmaceutical care of 
patients with asthma provided by community pharmacies in Hamburg city resulted in a clear positive 
impact on management of asthma and quality of life of the patients (Pharm J, ٢٠٠١). 
 
Pharmacists solved problems in asthma management was reported by Narhi et al (٢٠٠٢), after the 
interventions, half of the patients reported that their problems have been solved, ٨٩٫٢٪ of the patients 
reported that they were satisfied with the education and counseling provided by the pharmacists. Kheir et 
al (٢٠٠١) investigated the impact of a specialist asthma service provided by community pharmacist to a 
sample of asthmatic patients, their results revealed a significant improvement in asthma-related quality of 
life after introduction of the service and that the pharmacists were able to identify, prevent and/or solve 
over ٤٠٠ drug-related problems.    
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
٤٫٢ Methods and Materials 
 
٤٫٢ ١ Study Area:  
 
The study was conducted in Shaab teaching hospital. More details about the hospital were given in 
chapter ٢. A meeting with the consultant physicians and other clinicians was held to discuss the 
research work. A verbal consent to take part in the study was provided by the patients. 
  
٤٫٢٫٢ Inclusion and Exclusion Criteria 
 
The inclusion criteria for a patient to enter the study were evidence of chronic asthma based on 
confirmation of its diagnosis by medical doctors, aged between ٢٠-٦٠ years, residence in 
Khartoum state. The exclusion criteria were patients with pregnancy, tuberculosis, mental 
disturbances, and listening or speaking problems. 
 
٤٫٢٫٣ Study Design and Sampling Strategy 
 
This study was carried out as prospective, randomized, controlled, and single-center trial from April ٢٠٠٣ 
to March ٢٠٠٤ to implement and evaluate a pharmaceutical care service for asthmatic patients. A sample 
of ١٠٠ patients was collected randomly from the patients attending the emergency department or the refer 
clinic. Simple random sampling was used for patients’ allocation either in the test or control group.  ٦٠ 
patients were in the therapeutic outcome monitoring group (TOM) and ٤٠ patients were in the control 
group.  
 
٤٫٢٫٤  Data Collection 
 
Data were collected via structured, developed and pre-tested questionnaire containing closed- and open-
ended questions. It included all the variables relevant to the objectives of the study (Annex ١). Some of 
data were collected via face to face personal interviewing of the patient, others were collected after 
clinical examination of the patients, which were done by the medical doctor and also laboratory 
investigations were achieved. All the variables of the study questionnaire were filled in for each patient in 
both groups after being agreed to participate in the study. The outcome measures were determined   
during the follow-up every two weeks for ٢٢ weeks. Interventions were implemented for drug therapy 
related problems that were identified in the TOM group, while the control group didn’t receive any 
intervention. 
 
 
٤٫٢٫٥ Outcome Measures and their  Evaluation 
 
a] Final Outcome Measures 
 
Frequency of acute attacks per week, frequency of nocturnal symptoms per week, frequency of using β٢ – 
agonist per week, days of sickness per week and rate of hospitalization pre- and post-study period. Each 
patient was given a card to record the occurrence of each of the above mentioned measures during the 
previous two weeks to every follow-up. 
 
b] Intermediate Outcome Measures 
 
١. Peak expiratory flow rate: It was measured by peak flow meter; the best of three measures was 
recorded during each follow-up of the patient. The predicted value of each patient was determined 
according to gender, age and height (Gibbs and Small, ٢٠٠٣). 
 
٢. Inhaler technique: The patient was observed while using the inhaler for the ١٠ steps and each correct 
step for the appropriate use of the inhaler was given  a score of ١ and the overall score out of ١٠ for each 
patient  was obtained by adding the scores of each correct step demonstrated by the patient.  
 
 ٣. Disease knowledge: It was assessed through asking each patient about three points (what is asthma?; 
what are the precipitating and aggravating factors?; and how he/she can assess the severity?) and the 
patient score was ١ for each correct answer and ٠ for the wrong one. 
 
٤. Drug knowledge: Each patient was asked about his/her drugs and to show, which drugs are for 
prevention or rescue therapy. A score of ١ indicated that the patient has good knowledge about the role of 
each drug in asthma management, while a score of ٠ means poor knowledge. 
 
٥. Patient compliance to drug therapy: It was assessed through three points (dose, frequency of doses, and 
duration of the treatment) and each patient scores ١ for each appropriate use of the above mentioned 
points and ٠ for each inappropriate one. 
 
٦. Patient compliance to non-drug therapy measures: It was assessed through three points (smoking 
cessation, environmental control and control of common cold and infections) and each patient scores ١ for 
the compliance with each measure.  
 ٧. Ratio of prescribing inhaled steroids to bronchodilators 
 
 
C) Assessment of Side-effects 
 
Incidence of side effects: Biochemical side effects were assessed via laboratory investigations, objective 
side effects through clinical examination and subjective side effects as reported by the patients. Side 
effects were recorded when the patients enrolled in the study and during the follow-up every two weeks 
for ٢٢ weeks. 
 
٤٫٢٫٦ Laboratory Procedures 
 
a) Samples Collection 
 
The patient’s hand or arm was cleaned with cotton wool and ٧٠٪ethanol to remove dirt and then blood 
sample of ٤-٥ml was taken using sterile disposable syringe and collected in two different containers, 
lithium heparin container for potassium test and potassium fluoride container for glucose test. Serum was 
separated by centrifugation for ٢ minutes and collected in plain containers using micropipette and 
disposable tips. 
 
b) Biochemical Procedure 
 
Biochemical tests include serum potassium and random blood glucose; these tests were done for each 
patient in the first day and then repeated every follow up.  
 
 
  Test                                              Method                                  Normal values according to the                                
                                                                                                          method used 
 
Serum potassium                       Flame photometer                            ٣٫٥-٥٫٣  mg/dl 
Random blood glucose Glucose oxidase method                  ٨٠-١٢٠ mg/dl 
 
٤٫٢٫٧ Data Analysis 
 
Data was analyzed by SPSS software program version ١١.Paired sample test was used for analysis of 
normally distributed data and Wilcoxon test for data, which were not normally distributed .The level of 
significance P <٠٫٠٥. 
  
 
 
٤٫٢٫٨  Pilot Study: 
  
A pilot study of data collection, entry and analysis was conducted on ١٠ patients prior to the study to 
ensure validity and reliability of the data collection and the results of the study.  Questionnaires used in 
the pilot study were excluded from the study sample.  
 
٤٫٢٫٩  Materials 
 
The following equipment were used in the present work: 
       
Equipment                                                Source 
Sphygmanometer                                       KENZMEDICO CO. -  Japan 
Stethoscope                                                Littman -Germany    
Peak flow meter                                         AIRMED- England 
Weighing scale                                           NIKAI – Japan 
Disposable syringes                                    Shifa medical syringes- Saudia Arabia 
Measuring tape 
 
   
Drugs 
 
The following drugs were given for patients in both groups. 
 
    Drug                                                                                        Source 
Salbutamol inhaler ١٠٠mcg/puff (Ventolin®)    Glaxo- Wellcome England 
Salmeterol inhaler ٥٠ mcg/puff (Serevent®)                                   Glaxo- Wellcome England 
Beclomethasone inhaler ٥٠ mcg/ puff (Becotide®)                           Glaxo- Wellcome England 
Fluticasone dipropionate inhaler ٥٠ and ١٢٥ mcg/puff (Flixotide®)    Glaxo- Wellcome England 
Budesonide ٢٠٠ and ٤٠٠mcg/puff (Pulmicort®)                                   Astra-Zeneca-Sweden 
Salbutamol tablets ٢mg (Butalin®)                                        Gulf pharmaceutical industries, 
                                                                                                     Ras Al Khaima, U.A.E.                             
 
٤٫٣ Results and Discussion 
 
٤٫٣٫١ Demographic Data of the Study Population 
 
Table ٤٫١ shows the distribution of patients according to their number during the study period. The study 
included ٦٠ patients in the TOM group and ٤٠ patients in the control group. During the study period ١٢ 
patients of the TOM group and ١٠ patients of the control group were dropped out. From the TOM group 
one patient was died at his home after ٦ weeks from his contribution in the study due to acute severe 
asthmatic attack and two patients changed their residence and found it difficult to come every two weeks 
to Shaab hospital, others felt that they are fine and there is no need to attend the follow-up. From the 
control group two patients get pregnant, but the rest of patients dropped out without obvious reasons. 
 
Table ٤٫١ Distribution of patients according to their number during the study period  
 
Number of Patients Control TOM 
Baseline Enrollment ٤٠ ٦٠ 
Follow-Up Weeks   
٢ weeks ٣٤ ٥٨ 
٤weeks ٣٣ ٥٦ 
٦ weeks ٣٢ ٥٥ 
٨ weeks ٣٠ ٥٢ 
١٠ weeks ٣٠ ٥٢ 
١٢ weeks ٣٠ ٥١ 
١٤ weeks ٣٠ ٤٨ 
١٦ weeks ٣٠ ٤٨ 
١٨ weeks ٣٠ ٤٨ 
٢٠weeks ٣٠ ٤٨ 
٢٢ weeks ٣٠ ٤٨ 
 
 
In the control group, the study population enrolled was ٣٥٪ (١٤) males and ٦٥٪ (٢٦) females, while those 
in the TOM group were ٤٨٫٧ % (٢٩) males and ٥١٫٣٪ (٣١) females. The percentage of females in both 
groups was non-significantly higher than that of males. In Sudan, Abuobieda (٢٠٠١) reported a non-
significant higher prevalence of asthma in males than in females. 
 
 Table ٤٫٢ and figure ٤٫١ show the distribution of patients according to their age groups .In TOM group 
the majority of patients were aged between ٣١-٤٠ years while in control group the largest proportion were 
in the age group of ٢٠-٣٠ years. In Sudan, there was no available statistical data about the prevalence of 
asthma according to age, in this study the prevalence of asthma is high in the age group ٢٠-٤٠ years. Data 
from other countries showed that in Swiss population asthma was more prevalent in the age group of ٢٥-
٣٠ years, and in Australia it was reported that one child in six under the age of ١٦ is affected by asthma 
(WHO ٢٠٠٠). Glen (٢٠٠٠) reported that in USA the highest rate of asthma death is by the age of ٢٥-٣٤ 
years. 
 
Table ٤٫٢ Distribution of patients according to age groups 
 
Age of Patients (years) Number of Patients  
 Control TOM 
٢٠-٣٠ ١٦ ١٨ 
٣١-٤٠ ١٠ ٢٦ 
٤١-٥٠ ١١ ١٣ 
٥١-٦٠ ٣ ٣ 
 
 
Figure ٤٫١ Distribution of patients according to age groups 
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Table ٤٫٣ and figure ٤٫٢ show the distribution of patients according to their duration of being asthmatics. 
Most of the TOM patients were asthmatics for ١٠-٢٠ years, while most of control patients had the disease 
for less than ١٠ years      
 
 
Table ٤٫٣ Distribution of patients according to the duration of the disease 
 
Duration of disease (years)        Number of Patients  
 Control TOM 
<١٠ ٢٠ ١٤ 
١٠-٢٠ ١٣ ٣١ 
٢١-٣٠ ٦ ١٠ 
٣١-٤٠ ٠ ٢ 
٤١-٥٠ ١ ٣ 
 
 
Figure ٤٫٢ Distribution of patients according to the duration of the disease 
 
Table ٤٫٤ and figure ٤٫٣ show the distribution of patients according to their level of education. 
The majority of the patients in the TOM group were university graduates, while those in control 
group were of secondary education. 
 
Table ٤٫٤ Distribution of patients according to level of education 
 
Education level        Number of Patients  
 Control TOM 
Illiterate  ٤ ٥ 
Primary ٧ ١١ 
Secondary ٢١ ١٩ 
University graduate ٨ ٢٥ 
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Figure ٤٫٣ Distribution of patients according to their level of education 
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٤٫٣٫٢ Risk Factors of the Patients 
 
Table ٤٫٥ and figure ٤٫٤ show the distribution of patients according to smoking. In both groups the 
proportion of smokers was very small. WHO (٢٠٠٠) reported that tobacco smoking is one of the risk 
factors associated with the development of asthma. One patient in the control group and three from the 
TOM are smokers. The majority of patients in both groups are non-smokers. 
 
Table ٤٫٥ Distribution of patients according to smoking 
 
Smoking        Number of Patients  
 Control TOM 
Smoker ١ ٣ 
Non-smoker ٢٩ ٤٣ 
Stopped smoking ١٠ ١٤ 
 
 
 
 
 
 
 
 Figure ٤٫٤ Distribution of patients according to smoking 
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Table ٤٫٦ and figure ٤٫٥ show that allergic rhinitis was more prevalent in both groups. Allergic rhinitis is 
an important risk factor for asthma and its treatment from the very beginning of its inception is the 
effective way to prevent bronchial asthma (WHO, ٢٠٠٠). Studies confirmed that immunotherapy is 
capable of preventing the onset of asthma in children with allergic-rhinitis. It  was also proved that 
rhinitis and asthma were strictly linked, and up to ٥٠٪ of patients with rhinitis have asthma and rhinitis 
occur in up to ٨٠٪ of patients with asthma. It was demonstrated that the bronchial mucosal inflammation 
does not differ between asthmatics and rhinitics at least from the morphological point of view and this 
was confirmed by the fact that there was no difference in eosinophil count, interlukin-٥, and interlukin –
١٠ generation in bronchoalveolar lavage fluid from asthmatics and rhinitics. In patients with asthma and 
rhinitis, it was found that correct treatment of  allergic rhinitis with nasal steroids significantly reduced 
the rate of hospital admittance and emergency department visits due to asthma exacerbations (Giovanni et 
al, ٢٠٠٤).   
 
Table ٤٫٦ Distribution of patients according to history of allergy 
 
Type of allergy Number of Patients  
 Control TOM 
Allergic rhinitis ١٩ ٢٣ 
Skin allergy ٤ ٠ 
Rhinitis+skin allergy ١٠ ١٦ 
No allergy ٧ ٢١ 
 
 
 
Figure ٤٫٥ Distribution of patients according to history of allergy 
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Tables ٤٫٧, ٤٫٨ and figures ٤٫٦, ٤٫٧ show the distribution of patients according to family history of 
asthma and atopy, respectively. It was noticed that high percentage of patients in both groups had positive 
family history of asthma and atopy. In ٢٠٠١, WHO considered family history of asthma or allergy as risk 
factors for developing asthma and a study in the South Atlantic Island of Tristanda Cunha found that 
children with asthmatic parents were much more likely to develop asthma. In Sudan, Ahmed (١٩٩٦) 
reported that family history of atopy was often present in children with asthma and helpful in diagnosis of 
patients.  
 
Table ٤٫٧ Distribution of Patients According to family history of asthma 
 
Family History Number of Patients  
 Control TOM 
Positive ٢٩ ٤١ 
Negative ١١ ١٩ 
Figure ٤٫٦ Distribution of patients according to family history of asthma 
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Table ٤٫٨ Distribution of patients according to family history of atopy 
 
History Number of Patients  
 Control TOM 
Positive ٣٤ ٤٥ 
Negative ٦ ١٥ 
 
 
Figure ٤٫٧ Distribution of Patients According to family history of atopy 
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Table ٤٫٩ and figure ٤٫٨ show the distribution of patients according to the presence of concomitant 
diseases.  Malaria was the common concomitant disease for both groups when patients enrolled into the 
study. Awad (٢٠٠١) reported that malaria accounts for about ٢١٪ of all diseases in out-patient clinics and 
about ٣٢٪ of in-patient admissions; this indicates that malaria is one of the problematic diseases in Sudan. 
A lot of patients complaining that their asthma symptoms are aggravated with malaria but there are no 
evidence in the literature review indicating  the association between malaria and asthma, it is 
recommended that this relation should be investigated. 
 
Table ٤٫٩ Distribution of patients according to presence of concomitant diseases 
 
Disease        Number of Patients  
 Control TOM 
Diabetes ١ ٢ 
Hypertension ١ ٦ 
Malaria ٩ ١٢ 
 
 
Figure ٤٫٨ Distribution of patients according to presence of concomitant diseases 
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٤٫٣٫٣ Management of Asthma 
 
Table ٤٫١٠ and figure ٤٫٩ show the distribution of patients according to the sources from which they 
obtained their drugs. Pharmacy was the main source of drugs in both groups, other sources are relatives 
and / or friends, and this indicated the share of drugs within the community, which may lead to the 
irrational use of drugs.  
 
Table ٤٫١٠ Distribution of patients according to the source of obtaining their drugs 
 
Source Number of 
Patients 
 
 Control TOM 
Pharmacy ٣١ ٤٤ 
Pharmacy + Relatives and / or friends ٨ ١٢ 
Relatives and / or friends ١ ٤ 
 
 
Figure ٤٫٩ Distribution of patients according to the source of obtaining their drugs 
 
 
 
 
Despite the fact that drugs for asthma management were mainly obtained from the pharmacy, the 
patient counselling was not provided mainly by the pharmacists. Table ٤٫١١ and figure ٤٫١٠ 
show that the physician was the main provider of counselling to the majority of patients. It was 
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not known whether this was due to that patients trust physicians more than pharmacists or the 
pharmacists do not provide the counselling to the patients. Physicians are always over loaded 
with patients and they may have not the required time for appropriate counselling. Pharmacists 
as member of the health care team can help effectively in providing the appropriate patient 
counselling. A lot of researches worldwide confirmed that pharmacy practice had shed the role 
of dispensing to patient oriented practice. Narhi et al (٢٠٠٢) reported that ٨٩٫٢٪ of the patients 
in their study were satisfied with the education and counselling provided by pharmacists, which 
is a significant higher percentage than for physicians and nurses.Patient education and 
counseling are of great importance in asthma management since they lead to increased patient 
confidence in ability to self –manage asthma, decrease hospital admission rates and emergency 
visits and improving compliance and quality of life (Gibbs and Protlock, ٢٠٠١).  
 
In ١٩٨٧, FDA reported ١٢،٠٠٠ deaths and ١٥،٠٠٠ hospitalizations due to adverse drug reactions, these 
adverse reactions can be reduced by  providing pharmaceutical services, which can also reduce the length 
of hospital stays and the cost of care (Helper and Strand ١٩٩٠). Nadir et al (٢٠٠١) reported that during 
their study pharmacists were able to identify, prevent or resolve over ٤٠٠ drug-related problems. So 
pharmacists should accept their social mandate to ensure safety and effectiveness of drug therapy for the 
individual patient and set new practice standards and cooperate with other health care professionals for 
the patients benefit. Implementation of pharmaceutical care service in private and public pharmacies is of 
greater importance, they could fill the role as communicators, collaborators and front- line health care 
members providing appropriate patient counselling and referring serious cases to medical doctors.  
 
Table ٤٫١١ Distribution of patients according to the provider of patient counseling 
 
Provider Number of Patients  
 Control TOM 
Pharmacists ٣ ٦ 
Physicians ١٠ ٢١ 
Pharmacists + physicians ٩ ٧ 
Self ٢ ٦ 
 
Figure ٤٫١٠ Distribution of patients according to the provider of patient counselling 
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Table ٤٫١٢ and figure ٤٫١١ show the distribution of patients according to their acceptability of using 
inhalers.  In both groups, the percentage of patients who do not accept the inhaler use was less than those 
who accepted its use. There are still wrong beliefs about the use of an inhaler in the Sudanese community 
such as its use indicates the deterioration of the disease condition to some patients, while others believe 
that it has cardiac side effects. Other group of patients does not prefer the use of the inhalers for economic 
reasons, as they are more expensive than oral drugs and for the same reason some physicians do not 
prescribe them for the patients. The topical application of drugs to the lungs can be accomplished by 
using inhalers and this approach produce a high local concentration in the lungs with low systemic 
delivery, thereby significantly improving therapeutic ratio by minimizing systemic side effects (Joel et 
al., ٢٠٠١) 
 
Table ٤٫١٢ Distribution of patients according to their acceptability of using inhalers 
 
Acceptability Number of Patients  
 Control TOM 
Yes ٢٩ ٤٣ 
No ١١ ١٧ 
 
 
 
Figure٤٫١١ Distribution of patients according to their acceptability of using inhalers 
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Concerning the patients’ compliance with the nebulizer use, a high percentage of patients in both groups 
have a good compliance as shown in table ٤٫١٣ and figure ٤٫١٢. Only ٧ patients (٤ TOM and ٣ control) 
have nebulizers at home. The reasons for non-compliance include that the masks were used by a large 
number of patients in the hospital and this would subject them to a high risk of acquiring infections. 
Others have bad experience of tremors and palpitations with nebulizers. The later reason was confirmed 
in this study that the doses of β٢-agonist administered to patients via nebulizers were high and this 
increased the risk of their adverse reactions. 
 
Table ٤٫١٣ Distribution of patients according to their acceptability of using nebulizer 
 
Acceptability        Number of Patients  
 Control TOM 
Yes ٣٥ ٥٢ 
 No ٥ ٨ 
 
 
 
 
 
 
 
Figure ٤٫١٢ Distribution of Patients According to their acceptability of using nebulizer 
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Table ٤٫١٤ and figure ٤٫١٣ show the distribution of patients according to their method of monitoring 
asthma. Symptomatic self-monitoring was the common ways of monitoring asthma in both groups. Thus 
the majority of patients did not use the appropriate means of monitoring their disease. A lot of patients did 
not know the peak flow meter because it not available even in the hospitals despite the fact that it is very 
cheap and of great value in monitoring asthmatic patients.   
Table ٤٫١٤ Distribution of patients according to their method of monitoring asthma 
Method Number of Patients  
 Control TOM 
Peak flow meter ١ ٠ 
Clinically ٢ ٠ 
Symptomatic self monitoring ٣٧ ٦٠ 
 
Figure ٤٫١٣ Distribution of patients according to their method of monitoring asthma 
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٤٫٣٫٤ Problems and Interventions  
 
Table ٤٫١٥ show the problems identified in the TOM group and the interventions implemented.  
 
Table ٤٫١٥ Drug therapy related problems and other problems identified in the intervention 
group  
 
Problem Percentage 
[Number] 
Suggested Intervention % Accepted and 
implemented 
١. Management of 
chronic asthma did 
not follow the British 
Thoracic Society 
guidelines 
٦٨٫٣ % (٤١) The prescribers were informed 
about the appropriate individual 
management for each patient. 
١٠٠٪  
٢. Inappropriate dose 
of oral prednisolone 
١٣٫٣٪(٨) The prescribers were informed 
about the appropriate dose 
١٠٠% 
٣. Chronic use of 
prednisolone instead 
of inhaled steroids 
٤٣٫٣٪(٢٦) The prescribers and patients were 
informed about the advantages of 
inhaled steroids and the differences 
in side effects between oral and 
inhaled steroids 
٨١٪ 
٤. Refusal of using 
inhalers by the 
patients  
٢٨٫٣٪(١٧) The patients were informed about 
the difference in side effects 
between oral and inhalation 
therapy and advantages of 
inhalational therapy  
٩٤٫١٪  
٥. Absence of inhaled 
corticosteroids in the 
patient regimen 
٥٣٫٣٪ (٣٢) The prescribers were informed 
about the importance of inhaled 
corticosteroids as preventive 
therapy. 
١٠٠٪ 
٦. Chronic use of oral 
β٢-agonist instead of 
inhaled therapy 
٣١٫٧٪(١٩) The prescribers and patients were 
informed about the advantages of 
inhaled β٢-agonist and the 
difference in side effects between 
oral and inhaled therapy 
٩٣٫٣٪ 
 
 
 
 
 
 
 
 
٧. Prescribing of 
Terbutaline with 
Salbutamol 
١٫٧٪(١) The prescriber was informed about 
the risk of adverse effects 
associated with the use of  two β٢-
agonists 
١٠٠٪ 
٨. Inappropriate 
prescribing of 
Norfloxacin for chest 
infection 
١٫٧٪(١) The prescriber was informed that it 
was not the appropriate drug. 
١٠٠٪ 
٩. Use of peak flow 
meters for monitoring 
١٠٠٪ (٦٠) Its value and importance was 
explained to the patients 
٥٪, it was accepted 
but due to its non-
availability in 
Sudan people were 
not able to get it  
١٠. Inadequate 
knowledge about the 
role of each drug in 
treatment of therapy 
٤٨٫٣٪(٢٩) Patients were informed about the 
role of each drug in their treatment 
of asthma 
١٠٠٪ 
١١. Inappropriate 
technique of the use 
of inhalers 
٨١٫٧٪ (٤٩) Patients informed about the correct 
inhaler technique according to 
standard inhaler technique chart 
١٠٠٪ 
١٢. Side-effects 
 
a] Oral thrush 
 
 
 
 
 
b] Hyperglyacemia 
(prednisolone) 
 
 
 
c] Tremors, 
palpitations as side 
effects 
 
 
١٦٫٧٪(١٠) 
 
 
 
 
 
١٫٧٪(١) 
 
 
 
 
 
٥٦٫٧٪(٣٤) 
 
 
 
Patients prescribed Mycostatin oral 
suspension and counselled about 
rinsing their mouth after using 
steroid inhalers and changing their 
tooth brushes continuously. 
 
The Patient was advised to stop 
prednisolone and was referred to 
an endocrinologist  
 
 
 
The oral use of  
β٢-agonist was recommended to be 
stopped and replaced by inhaled 
β٢-agonist as required. 
 
 
١٠٠٪  
 
 
 
 
 
٠٪ [The Patient 
refused to see the 
doctor and continue 
in taking 
prednisolone] 
 
٨٨٫٨٪ 
  
 
 
١٣. Drug-interactions 
 
 
١٦٫٧٪(١٠) 
 
 
Prescribers were informed about 
the risk of adverse effects 
associated with concomitant 
administration of Erythromycin 
and Theophylline  
 
 
٣٧٫٥٪ 
١٤. Patients non-
compliance to the 
treatment 
٦٥ % (٣٩) The patients were educated about 
the appropriate dose, frequency 
and the importance of the 
continued drug therapy 
١٠٠٪ 
١٥. Self- 
administration of 
direct I.V 
Aminophylline 
٣٫٣٪(٢) Patients informed about the serious 
adverse effects that could result 
from  this inappropriate use. 
٥٠٪ 
١٦.Undetected 
hypertension 
٣٫٣٪(٢) Patients’ BP was followed up and 
antihypertensive drugs were 
prescribed 
١٠٠٪ [controlled] 
١٧. Smoking ٥٪(٣) The patients were informed about 
smoking and its serious 
complications  
٠٪ still they are 
smoking but not 
frequently 
١٨. Allergic rhinitis ٦٥٪(٣٩) The patients were referred to ENT 
hospital 
٢٥٫٦٪ 
 
 
 
 
 
 
 
 
 
 
٤٫٣٫٤ Outcome Measures for the Evaluation of the Impact of Implementing the 
Pharmaceutical Care Service 
 
The mean (standard deviation) differences of the patients outcome effect variables are presented in tables 
٤٫١٦ –٤٫٢٦ for  the TOM and control groups together from ٠ to ٢٢ weeks and P values for the paired 
sample t-test and Wilcoxon test. 
 
a) Final Outcome Measures 
 
Table ٤٫١٦ shows that the change in the frequency of acute attacks per week, at the baseline enrollment, 
there was no significant difference (P>٠٫٠٥) between both groups in the number of acute attacks per 
week. The frequency was decreased significantly within both groups during the follow-up weeks, a highly 
significant decrease was achieved the TOM group when compared to the control group. The difference in 
reduction was significantly more in the TOM group except at the ١٢ weeks of follow-up the difference 
was non-significant (P>٠٫٠٥).  
 
Table ٤٫١٦ Frequency of acute attacks per week 
 
Group Frequency of acute attacks per week 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
٢٫١٠ 
(٠٫١٧) 
-١٫٤٣ 
(٠٫١٦) 
-١٫٨٣ 
(٠٫١٦) 
-١٫٨٥ 
(٠٫١٦) 
-١٫٩١ 
(٠٫١٧) 
-١٫٨١ 
(٠٫١٦) 
-١٫٨٣ 
(٠٫١٧) 
-١٫٩١ 
(٠٫١٦) 
-٢٫٠٤ 
(٠٫١٧) 
-١٫٨٩ 
(٠٫١٧) 
-١٫٩٣ 
(٠٫١٧) 
-١٫٩١ 
(٠٫١٨) 
Control 
 
١٫٤٠ 
(٠٫١٣) 
-٠٫٦٣ 
(٠٫١٠) 
-٠٫٩٦ 
(٠٫١) 
-٠٫٧٠ 
(٠٫١١) 
-٠٫٩ 
(٠٫١٢) 
-٠٫٩٦ 
(٠٫١٣) 
-١٫١٠ 
(٠٫١٣) 
-٠٫٨٦ 
(٠٫١٤) 
-٠٫٩٣ 
(٠٫١١) 
-٠٫٩ 
(٠٫١٣) 
-٠٫٩٣ 
(٠٫١٢) 
-١٫٠ 
(٠٫١٤) 
P-value 
 
٠٫٠٨ ٠٫٠٣ ٠٫٠٣ ٠٫٠٠ ٠٫٠٢ ٠٫٠٢ ٠٫٠٦ ٠٫٠٢ ٠٫٠١ ٠٫٠٢ ٠٫٠١ ٠٫٠٣ 
 
• -  [Decreased] 
• wks [ Weeks] 
 
 Table ٤٫١٧ shows the change in the frequency of the nocturnal asthma symptoms during the study period 
in the TOM and control groups. At the baseline enrollment, there was no significant difference (P>٠٫٠٥) 
between both groups in the frequency of the nocturnal asthma symptoms. Both groups have shown a 
significant decrease in the frequency of nocturnal symptoms. On comparing the reduction in the 
frequency between the groups, it was found that the TOM group had a greater significant reduction than 
the control group during the ٢٠th and ٢٢nd weeks of the follow-up.  
Table ٤٫١٧ Frequency of nocturnal asthma symptoms per week 
 
Group Frequency of nocturnal symptoms per week 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
٤٫٣٥ 
(٠٫٣) 
-٠٫٨٨ 
(٠٫٠٤) 
-٢٫٣٨ 
(٠٫٢) 
-٣٫١٢ 
(٠٫٣) 
-٣٫٤٥ 
(٠٫٣١) 
-٣٫٥٨ 
(٠٫٣٤) 
-٣٫٢٢ 
(٠٫٣٤) 
-٣٫٧٥ 
(٠٫٣٢) 
-٣٫٠٢ 
(٠٫٣٣) 
-٣٫٣٧ 
(٠٫٣٣) 
-٣٫٥٢ 
(٠٫٣٥) 
-٣٫٤٥ 
(٠٫٣٣) 
Control 
 
٣٫١٠ 
(٠٫٢٩) 
-٠٫٢٦ 
(٠٫٠٣) 
-٠٫٨٨ 
(٠٫٠٥) 
-١٫٥١ 
(٠٫٣٩) 
-١٫٣٦ 
(٠٫١٨) 
-١٫٥٦ 
(٠٫١٦) 
-١٫٥٨ 
(٠٫٢٦) 
-١٫٧٦ 
(٠٫١٨) 
-١٫٦١ 
(٠٫١٧) 
-١٫٣٥ 
(٠٫١٣) 
-١٫٦٣ 
(٠٫١٦) 
-١٫٠٨ 
(٠٫١٦) 
P-value 
 
٠٫١٤ ٠٫٦٨ ٠٫٣٥ ٠٫٢٥ ٠٫٠٦ ٠٫١١ ٠٫٠٨ ٠٫٠٦ ٠٫٢٢ ٠٫٠٦ ٠٫٠٤ ٠٫٠٢ 
• -  [Decreased] 
• wks [ Weeks] 
 
Table ٤٫١٨ shows the change in the frequency of  using inhaled β٢-agonist per week, at the baseline 
enrollment, there was no significant difference (P>٠٫٠٥) between both groups  There was a statistically 
significant decrease (P< ٠٫٠٥) in the use of β٢-agonist per week within the groups during the follow-
up weeks. A highly significant reduction (P<٠٫٠٥) was achieved in the TOM group from the ٦th week to 
the ٢٢nd week when compared to the control group.  
 
Table ٤٫١٨ Frequency of using Inhaled β٢-agonist per week 
 
Group Frequency of using - β٢ agonist per week 
[Mean (SD)] 
 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
٢٦٫٨ 
(٢٫٤) 
-٩٫٠ 
(٠٫٨) 
-١١٫٥ 
(١٫٤) 
-١٦٫٠ 
(١٫٨) 
-١٦٫٣ 
(١٫٧) 
-١٨٫٩ 
(١٫٩) 
-١٩٫٠ 
(٢٫٠) 
-١٩٫٥ 
(١٫٩) 
-١٨٫٩ 
(٢٫٠) 
-١٦٫٨ 
(١٫٨) 
-١٩٫٨ 
(٢٫٠) 
-١٩٫٩ 
(٢٫١) 
Control 
 
١٩٫١ 
(٢٫١) 
-٣٫٣ 
(٣٫٢) 
-٨٫٣ 
(٠٫٨) 
-٠٫٩٠ 
(٠٫٠٩) 
-٣٫١ 
(٢٫٦) 
-٣٫٨ 
(٣٫٧) 
-٥٫٢٦ 
(٠٫٦) 
-٤٫٥٣ 
(٠٫٤) 
-٨٫٩٣ 
(٠٫٩) 
-٧٫٢ 
(٠٫٧) 
-٦٫٥٦ 
(٠٫٨) 
-٣٫٣ 
(٠٫٣) 
P-value 
 
٠٫١٧٢ ٠٫٣٥٣ ٠٫٤٥٩ ٠٫٠٠٢ ٠٫٠٣٦ ٠٫٠١٣ ٠٫٠٢٢ ٠٫٠٢٥ ٠٫٠٤٥ ٠٫٠٩٨ ٠٫٠٣١ ٠٫٠١٨ 
• -  [Decreased] 
• wks [ Weeks] 
 
 
 
 
 
Table ٤٫١٩ shows the change in the in days of sickness per week, at the baseline enrollment, there was no 
significant difference (P>٠٫٠٥) between both groups. A significant reduction (P<٠٫٠٥) in the days of 
sickness was shown in the TOM group, while in the control group the days of sickness were increased .  
Table ٤٫٢٠ shows the rate of hospitalization per ٦ months in both groups before being enrolled in the 
study and at the end of the study period. It was decreased significantly (P<٠٫٠٥) in the TOM group, while 
increased non-significantly (P>٠٫٠٥) in the control group. 
 
Table ٤٫١٩ Days of sickness per week 
Group Days of sickness per week 
                                                                                   [Mean (SD)] 
 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
١٫٤٧ 
(٠٫١٦) 
-٠٫٤٣ 
(٠٫٢٣) 
-١٫١٢ 
(٠٫١٧) 
-٠٫٨٩ 
(٠٫٠٧) 
-٠٫٨٧ 
(٠٫٠٨) 
-١٫٢٠ 
(٠٫١٥) 
-١٫٣٩ 
(٠٫١٦) 
-١٫٣٩ 
(٠٫١٧) 
-١٫٣٣ 
(٠٫١٦) 
-١٫١٨ 
(٠٫١٨) 
-١٫٢٢ 
(٠٫١٣) 
-١٫٣٩ 
(٠٫١٤) 
Control 
 
٠٫٩٣ 
(٠٫١٥) 
+٠٫٦٦ 
(٠٫٠٥) 
+ 
٠٫٣٣ 
(٠٫٠٤) 
+٠٫٤٠ 
(٠٫٠٣) 
+ 
٠٫١٦ 
(٠٫٠٢) 
+ 
٠٫٢٣ 
(٠٫٠٢) 
+ 
٠٫٠٦ 
(٠٫٠١) 
+ 
٠٫١٣ 
(٠٫٠٢) 
+ 
٠٫١٠ 
(٠٫٠١) 
+ 
٠٫٤٣ 
(٠٫٠٢) 
+ 
٠٫٨٦ 
(٠٫٠٦) 
+ 
٠٫٩٦ 
(٠٫٠٩) 
P-value 
 
٠٫٦٣ ٠٫٢٤ ٠٫٠٤٥ ٠٫٠٧٦ ٠٫٤٢١ ٠٫٠٥٢ ٠٫٠١٥ ٠٫٠١٧ ٠٫٠٥ ٠٫٠٣٣ ٠٫٠٠٦ ٠٫٠٠٢ 
• -  [Decreased] 
• + [Increased] 
• wks [ Weeks] 
 
 
Table ٤٫٢٠ Rate of hospitalization per ٦ months before enrollment in the study and at the 
end of the study period  
 
 
 
 
 
 
 
 
 
 
Hospitalization rate [Mean (SD)] 
Group Before the study After the study
TOM ٠٫٧٢٩(٠٫٠٨) ٠٫٢٧٠(٠٫٠٢) 
P-value ٠٫٠٠٩ 
Control ٠٫٣٠(٠٫٠٢) ٠٫٥٣(٠٫٠٥) 
P- value ٠٫٢٥٧ 
The results of the present study have shown that patients in the TOM group had better final outcomes 
than patients in the control group. TOM patients had significant better asthma symptom status, reduction 
in the occurrence of nocturnal asthma symptoms, the use of inhaled β٢  agonists, days of sickness and rate 
of hospitalization.  Although the number of patients in this study were small, its findings imply that the 
pharmacist’s intervention had an effect in terms of improving the quality of care for asthmatic patients 
and this was shown through the improvement of the final outcome measures in the TOM group. 
 
A similar result was reported by Schultz et al (٢٠٠٠). In ٢٠٠١,  Herborg et al had shown that  
pharmacists’ intervention decreased the consumption of β٢ - agonists in the intervention group more 
significantly than in the control. The patients in the intervention group showed a diminished risk of sick 
days during the study year and the proportion of sick days per patient per month (PPPM) relative to 
control tended to decrease over the ١٢ months by about ٥٪ each month but over the last ٤ months of the 
study, the patients in the intervention group reported about ٢٥٪ as many sick days as patients in control 
group. 
 
Cordina et al.(٢٠٠١) reported that significantly more patients in the intervention group than in the control 
group reported nighttime wheezing all the time or most of the time at the final assessment point. They 
also showed in their study that no member of the intervention group was hospitalized during the study 
period but ٨ patients in the control group were hospitalized due to asthma exacerbations and the self –
reported hospitalization rates were significantly different between the two groups. She reported that the 
statistical analysis did not reveal any significant differences in the responses between the intervention and 
control groups regarding days lost from work or school. In ١٩٩٥, Boulet et al  found that a decreased 
number of days lost from work in their intervention group compared with the control group. 
 
Both groups in this study demonstrated improved outcomes during the study period, this may have tended 
to reduce the apparent effect size of the pharmaceutical service. A number of factors could be at work 
here. First, the identification of the drug-related problems in the TOM group and their discussion with the 
medical doctors have changed their prescribing patterns and they have implemented the majority of these 
interventions to the control group providing some new care practices. Second, filling out questionnaires 
and meeting at evaluation sessions may be an educational intervention itself. The design of this study 
imposed certain limitations. Two hospitals, one for the TOM and the other for the control patients were 
necessary to avoid any overlap between the intervention and control groups.  The dropouts of the patients 
decreased the study sample, some of the healthiest patients dropped out stating that they did not require 
the service for ٦ months.  
 
 
 
 
 b) Intermediate Outcome Measures 
 
Table ٤٫٢١ shows the change in the peak expiratory flow rate in both groups, at the baseline enrollment, 
there was no significant difference (P>٠٫٠٥) between both groups. The PEFR was measured every two 
weeks during the follow-up and not on daily basis and that was mainly due to the lack of availability of 
the required number to be given to the patients. There was a significant increase (P>٠٫٠٥) in PEFR of 
patients in both groups (P < ٠٫٠٥) throughout the study period. The change in the PEFR between both 
groups was not statistically significant (P>٠٫٠٥). The TOM patients showed a higher mean percentage of 
improvement in the PEFR from the ١٢th week till the end of the study.  
 
In ٢٠٠١,Cordina et al. and Herborg et al reported a non- significant difference between the intervention 
and control groups in the improvement of the PEFR. Balley et al (١٩٩٠) reported improvements in 
morning PEFR for the intervention groups compared with controls. Bergmann et al (١٩٩٢) showed 
improvements in FEV١ in the intervention groups. Grainger-Rousseau (١٩٩٢) and Allen et al (١٩٩٥) 
reported that intervention programs with ambulatory patients with asthma showed no changes.   
 
Table ٤٫٢١ Peak Expiratory Flow Rate 
 
Group 
 
PEFR 
[Mean (SD)] 
 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks
TOM 
 
٢٥٣٫٩ 
(١٠٫٥) 
+٢٦٫٠٤ 
(٣٫٧) 
+٢٨٫٧٥ 
(٢٫٧١) 
+٤٣٫٧٥ 
(٣٫١١) 
+٤٨٫١٢ 
(٤٫٢) 
+٤٥٫٦٢ 
(٤٫٤١) 
+٥١٫٢٥ 
(٤٫٦٣) 
+٥٣٫٣٣ 
(٥٫٧١) 
+٦٦٫٢٥ 
(٧٫١٨) 
+٥٧٫٩١ 
(٥٫٥٣) 
+٥١٫٠٤ 
(٥٫١٥) 
+٥١٫٨٧ 
(٥٫٥٣) 
Control 
 
٢٥١٫٦ 
(٩٫٩) 
+٥٢٫٣٣ 
(٦٫٢١) 
+٦١٫٣٣ 
(٦٫٤٤) 
+٥٣ 
(٥٫٢) 
+٤٧٫٦٦ 
(٤٫٨٩) 
+٤١٫٣٣ 
(٤٫٨٥) 
+٤٤٫٦٦ 
(٤٫٢٦) 
+٤٢٫٣٣ 
(٥٫٨٢) 
+٣٨ 
(٣٫٦٨) 
+٤٣٫٦٦ 
(٤٫٥٨) 
+٣٩٫٠ 
(٣٫٨٢) 
+٣٠٫٦٦ 
(٣٫١٥)
P-value 
 
٠٫١٢٤ ٠٫٥٠ ٠٫٤٣٧ ٠٫٧٤١ ٠٫٥٧٨ ٠٫٣٢٣ ٠٫٣٢٩ ٠٫١٧٨ ٠٫٠٨٤ ٠٫٤١٥ ٠٫١٩٤ ٠٫٠٥١ 
 
• + [Increased] 
• wks [ Weeks] 
 
Table ٤٫٢٢ shows the change in the score for the technique of the inhaler use, at the baseline enrollment, 
there was no significant difference (P>٠٫٠٥) between both groups. There was a significant improvement 
in the score for the inhalation technique within both groups during the follow-up period. The patients in 
the TOM group showed a highly significant greater improvement (P<٠٫٠٥) than those in the control. 
Most of asthma medications are given by inhalation and without proper technique and optimal medication 
delivery, drugs will not be as effective as it could be, and the fault would not be necessarily with 
medication but due to inadequate administration, thus, the proper technique must be taught to the patients 
(Peebles et al., ٢٠٠٢). 
  
Campeu (٢٠٠٢) reported that ٨٠٪ of patients failed to actuate and inhale simultaneously when using 
MDI, while others positioned the canister close to the chest or away from the mouth. The dangerous 
problem is that some patients may inhale objects such as earrings or pen tops which ledged in the device 
if the caps are lost. She also stated that inhaler technique should be checked annually or ideally every visit 
to reinforce good technique. Also she pointed that poor inhaler technique reduces the disease control. 
 
Cordina et al. (٢٠٠١) reported that significant difference between scores of baseline and ١٢ month 
evaluation was noticed in the intervention group, while Herborg et al (٢٠٠١), showed that the number of 
inhalation errors decreased for both intervention and control groups, but the intervention group showed 
more significant decrease in the inhalation errors than the control group.  
 
Table ٤٫٢٢ Technique of inhaler use 
 
Group Technique of inhaler use 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks
TOM 
 
٤٫٥٦ 
(٠٫٣٨) 
+ 
١٫٨٩ 
(٠٫١٨) 
+ 
٣٫١٤ 
(٠٫٢٨) 
+ 
٣٫٦٢ 
(٠٫٣٧) 
+ 
٣٫٨٣ 
(٠٫٣٨) 
+ ٤٫٢٢ 
(٠٫٤٨) 
+ ٤٫٢٥ 
(٠٫٤٢) 
+ ٤٫٤٧ 
(٠٫٥٧) 
+ ٤٫٧ 
(٠٫٥٨) 
+ ٤٫٨٥ 
(٠٫٤٥) 
+ ٤٫٨٥ 
(٠٫٨٣) 
+ ٤٫٩١ 
(٠٫٤٧) 
Control 
 
٦٫٢٣ 
(٠٫٥٢) 
+ ٠٫٨٦ 
(٠٫٠٧) 
+ 
٠٫٧٣ 
(٠٫٠٦) 
+ 
٠٫٧٦ 
(٠٫٠٨) 
+ 
٠٫٩٠ 
(٠٫٠٩) 
+ ١٫٠٣ 
(٠٫١٧) 
+ ١٫٠٦ 
(٠٫١٨) 
+ ١٫٠٦ 
(٠٫١٨) 
+ ١٫٠٦ 
(٠٫١٨) 
+ ١٫٠٦ 
(٠٫١٨) 
+ ١٫٠٦ 
(٠٫١٨) 
+ ١٫٠٦ 
(٠٫١٨) 
P-value 
  
٠٫٠٣ ٠٫٠٤ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠ ٠٫٠٠
 
• + [Increased] 
• wks [ Weeks] 
 
Table ٤٫٢٣ shows the change in the score for assessing asthma knowledge in both groups, at the baseline 
enrollment, there was no significant difference (P>٠٫٠٥) between both groups. The TOM group showed a 
highly significant improvement (P<٠٫٠٥) in asthma knowledge, while those in the control group showed 
a non-significant improvement (P>٠٫٠٥). The improvement in asthma knowledge was significantly 
greater in the TOM group than in the control (P<٠٫٠٥). This improvement is consistent with the 
improvement in the final outcomes that were shown in the present results, other studies reported smaller 
reductions in morbidity associated with significant improvements in asthma knowledge (Allen et al, 
١٩٩٥; Boulet et al, ١٩٩٥ and Schultz et al, ٢٠٠٠), however, the relationship between knowledge and 
morbidity may not be a simple one. Thus, the improvement in asthma knowledge is essential to improve 
the asthmatic patient quality of life. In ٢٠٠١, Herborg et al (٢٠٠١) reported an improvement in asthma 
knowledge in both intervention and control groups, but it was more significant in the TOM group. A 
highly significant improvement in the knowledge of patients who were provided by a pharmaceutical care 
over a course of one year was reported by the German study.. 
 
Table ٤٫٢٣ Asthma Knowledge 
 
Group Disease knowledge 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks
TOM 
 
١٫٠٦ 
(٠٫١٥) 
+ ٠٫٩٧ 
(٠٫٠٨) 
+ ١٫٥٢ 
(٠٫١٤) 
+ ١٫٧٩ 
(٠٫١٢) 
+ ١٫٨٣ 
(٠٫١٧) 
+ ١٫٨٥ 
(٠٫١٨) 
+ ١٫٨٧ 
(٠٫٢١) 
+ ١٫٨٧ 
(٠٫٢١) 
+ ١٫٨٧ 
(٠٫٢١) 
+ ١٫٨٧ 
(٠٫٢١) 
+ ١٫٨٧ 
(٠٫٢١) 
+ ١٫٨٧ 
(٠٫٢١) 
Control 
 
١٫٧ 
(٠٫١٨) 
+ ٠٫١٦ 
(٠٫١٦) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
P-value 
 
٠٫٠٧ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ 
• + [Increased] 
• wks [ Weeks] 
 
Table ٤٫٢٣ shows the change in the score for assessing drug knowledge in both groups, at the baseline 
enrollment, there was no significant difference (P>٠٫٠٥) between both groups. Both groups showed a 
significant improvement in the drug knowledge (P<٠٫٠٥). The improvement in the TOM group was non-
significantly (P>٠٫٠٥) greater than that in the control group. The knowledge about the role of each drug 
in the management of asthma is quite essential to reinforce the appropriate management of asthma. 
 
 
 
 
 
 
Table ٤٫٢٤ Drug knowledge 
 
Group Drug knowledge 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks
TOM 
 
٠٫٥٦ 
(٠٫٠٥) 
+ ٠٫٣١ 
(٠٫٠٤) 
+ ٠٫٣٧ 
(٠٫٠٤) 
+ ٠٫٣٩ 
(٠٫٠٤) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
+ ٠٫٤٣ 
(٠٫٠٥) 
Control 
 
٠٫٤٠ 
(٠٫٠٤) 
+ ٠٫٢ 
(٠٫٠٣) 
+ ٠٫٢٣ 
(٠٫٣) 
+ ٠٫٢٦ 
(٠٫٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
P-value 
 
٠٫٥٦ ٠٫١٦٦ ٠٫٠٧١ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩ ٠٫٠٥٩
 
Table ٤٫٢٥ shows the change in the score of the patients’ compliance to the drug therapy in both groups, 
at the baseline enrollment, there was no significant difference (P>٠٫٠٥) between both groups. The TOM 
group showed a significant improvement (P>٠٫٠٥) in the patients’ compliance, while that in the control 
group was non-significant (P>٠٫٠٥).  The improvement was significantly greater (P<٠٫٠٥) in the TOM 
than in the control at the ١٠th , ١٢th ,١٨th ,٢٠th  and ٢٢nd  follow-up weeks of evaluation. It was noticed 
during the study period that a lot of patients might stop taking their treatment particularly the preventive 
therapy due to financial constraints, reasons, thus, they prefer to purchase their rescue therapy than 
preventive therapy. Cordina et al. (٢٠٠١) reported a non-significant difference between the intervention 
and the control groups compliance at ١٢ months of evaluation. 
 
Table ٤٫٢٥ Patients compliance to drug therapy 
 
Group Patient Compliance 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks
TOM 
 
١٫٣٥ 
(٠٫١٤) 
+ ١٫٢٧ 
(٠٫١٤) 
+ ١٫٣٥ 
(٠٫١٤) 
+ ١٫٢٢ 
(٠٫١٣) 
+ ١٫١٦ 
(٠٫١٥) 
+ ١٫٣٩ 
(٠٫١٦) 
+ ١٫٣٧ 
(٠٫١٦) 
+ ١٫٢٥ 
(٠٫١٢) 
+ ٠٫٩٣ 
(٠٫١٠) 
+ ١٫٣٧ 
(٠٫١٥) 
+ ١٫٣٧ 
(٠٫١٤) 
+ ١٫٢٧ 
(٠٫١٢) 
Control 
 
١٫٦ 
(٠٫١٥) 
+ ٠٫٧٦ 
(٠٫٠٨) 
+ ٠٫٦ 
(٠٫٠٦) 
+ ١٫١٦ 
(٠٫١٢) 
+ ٠٫٨٦ 
(٠٫٠٩) 
+ ١٫٠ 
(٠٫١١) 
+ ٠٫٦ 
(٠٫٠٦) 
+ ٠٫٨٦ 
(٠٫٠٨) 
+ ٠٫٧ 
(٠٫٠٩) 
+ ٠٫٦٦ 
(٠٫٠٧) 
+ ٠٫٥٦ 
(٠٫٠٦) 
+ ٠٫٣٠ 
(٠٫٠٣) 
P-value 
  
٠٫٢٧٣ ٠٫٠٥٣ ٠٫٠٧١ ٠٫٢٩٣ ٠٫١٧٦ ٠٫٠٣٧ ٠٫٠١٢ ٠٫٠٧٦ ٠٫١٦٩ ٠٫٠٤٨ ٠٫٠١٩ ٠٫٠١١ 
 
Table ٤٫٢٦ shows the change in the score of the patients’ compliance to the non-drug therapy measures in 
both groups, at the baseline enrollment, there was no significant difference (P>٠٫٠٥) between both 
groups. The TOM group showed a significant improvement (P<٠٫٠٥) in compliance to non-drug therapy, 
while those in the control showed a non-significant improvement (P>٠٫٠٥). A highly significant greater 
improvement (P<٠٫٠٥) was achieved in the TOM group when compared to that in the control group. The 
restrictions to the environmental triggers were found to be the most resistant to the improvement in 
compliance to non-drug therapy, however, the identification and avoidance of triggers remains the best 
solution for these patients.  These results were similar to those reported by Kheir et al (٢٠٠٠). 
 
Table ٤٫٢٦ Patients’ Compliance to non-drug therapy measures 
 
Group General measures 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks
TOM 
 
١٫٢٥ 
(٠٫١٤) 
+ ٠٫٧٩ 
(٠٫٠٩) 
+ ١٫٠ 
(٠٫١٥) 
+ ١٫٢٩ 
(٠٫١٣) 
+ ١٫٤٥ 
(٠٫١٥) 
+ ١٫٦٢ 
(٠٫١٦) 
+ ١٫٦٢ 
(٠٫١٨) 
+ ١٫٦٢ 
(٠٫٢٠) 
+ ١٫٦٦ 
(٠٫١٧) 
+ ١٫٦٨ 
(٠٫١٨) 
+ ١٫٦٨ 
(٠٫١٧) 
+ ١٫٧ 
(٠٫١٨) 
Control 
 
١٫٥٦ 
(٠٫١٦) 
+ ٠٫١٦ 
(٠٫٠٢) 
+ ٠٫١٦ 
(٠٫٠٢) 
+ ٠٫١٦ 
(٠٫٠٢) 
+ ٠٫١٣ 
(٠٫٠١) 
+ ٠٫٢٣ 
(٠٫٠٣) 
+ ٠٫٢٣ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
+ ٠٫٢٦ 
(٠٫٠٣) 
P-value 
  
٠٫٢٢٣ ٠٫٠٠٥ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ ٠٫٠٠٠ 
 
Table ٤٫٢٧ shows the change in ratio of prescribing inhaled steroids to bronchodilators, at baseline 
enrollment, there was no significant difference between both groups (P<٠٫٠٥). The TOM group showed a 
highly significant increase in the ratio starting from the ٢nd week of the follow-up till the end of the study, 
while the control group showed a significant improvement in the ratio since ١٠th week of the follow-up. 
The TOM group revealed a highly significant greater improvement than the control group (P<٠٫٠٥). 
Salamzadeh et al (٢٠٠٠) reported that practices with low ratio of preventers to bronchodilators were of  
poor quality. These findings showed the improvement in the quality of prescribing in the TOM group. 
 
Table ٤٫٢٧ Ratio of inhaled steroids to bronchodilators 
Group Ratio of inhaled steroids to bronchodilators 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
٠٫٦ ٣٫٨ ٥ ٥٫٨ ٥٫٨ ٥٫٨ ٥٫٨ ٥٫٨ ٥٫٨ ٥٫٨ ٥٫٨ ٥٫٨ 
Control 
 
٠٫٨ ١ ١ ١٫٥ ٢٫٣ ٢٫٧ ٣٫٢ ٣٫٢ ٣٫٢ ٣٫٢ ٣٫٢ ٣٫٢ 
 
The findings of this study have shown that the patients in the TOM group had better intermediate 
outcomes than those in the control group. TOM patients had better improvement in the PEFR, technique 
of inhaler use, asthma and drug knowledge, patients’ compliance to drug and non-drug therapy and the 
ratio of prescribing inhaled steroids to bronchodilators. The face-to-face education of asthmatic patients 
in the TOM group facilitated the individual learning needs and provided patients interaction and their 
involvement in decisions regarding their appropriate treatment. 
 
The discussion topics include the concept of asthma being a chronic disease with airway changes, 
recognition of symptoms, differentiation between rescue and preventer drugs, their proper use and side-
effects, environmental control measures, individualized management plan and the importance of regular 
physician monitoring and follow-up. Although the number of patients in this study were small, its 
findings implies that the pharmacist’s intervention had an effect in terms of improving the quality of care 
for asthmatic patients and this was shown through the improvement of the intermediate outcome 
measures in the TOM group. Thus, the collaboration of pharmacists with physicians would improve the 
asthma management. 
 
Both groups in this study demonstrated improved outcomes during the study period; this may have tended 
to reduce the apparent effect size of the pharmaceutical service. A number of factors could be at work 
here. First, the identification of the drug-related problems in the TOM group and their discussion with the 
medical doctors have changed their prescribing patterns and they have implemented the majority of these 
interventions to the control group providing some new care practices. Second, filling out questionnaires 
and meeting at evaluation sessions may be an educational intervention itself. The design of this study 
imposed certain limitations. Two hospitals, one for the TOM and the other for the control patients were 
necessary to avoid any overlap between the intervention and control groups.  The dropouts of the patients 
decreased the study sample, some of the healthiest patients dropped out stating that they did not require 
the service for ٦ months.  
 
c) Assessment of Side-effects 
 
Table ٤٫٢٨ shows the percentage of patients with subjective and/or objective side effects, at baseline 
enrollment there was no significant difference between the groups (P>٠٫٠٥). There was a significant 
reduction (P<٠٫٠٥) in the percentage of patients with side-effects in both groups. The reduction of the 
patients with side effects in the TOM group was non-significantly greater (P>٠٫٠٥) than that in the 
control group. 
 
 
 
 
Table ٤٫٢٨ Percentage of patients with side-effects 
 
Group Percentage of patients reporting Side effects 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
٩١٫٦ % ٢٥٪ ٣٥٫٤٪ ١٢٫٥٪ ١٤٫٥ % ١٦٫٦ % ١٨٫٧٪  ١٤٫٥٪ ٨٫٣٪ ١٢٫٥٪ ١٤٫٥٪ ٨٫٣٪ 
Control 
 
٨٠٪ ٣٦٫٦٪ ٤٠٪ ٣٦٫٦٪ ٢٠٪ ٢٠٪ ١٣٫٣٪ ٢٣٫٣٪ ٢٠٪ ١٦٫٦٪ ١٦٫٦٪ ٦٫٦٪ 
 
 
Tables ٤٫٢٩ and ٤٫٣٠ show the mean serum potassium and blood glucose levels in both groups, 
respectively.  There was no significant change (P>٠٫٠٥) in the levels within the groups and between 
them. The present results showed that the incidence of hypokalaemia with the use of steroids and β٢ – 
agonists and hyperglycemia with the use of steroids were not common in patients on inhalation therapy. 
 
Table ٤٫٢٩ Serum Potassium levels 
Group Serum potassium levels 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
٣٫٥٢ 
(٠٫٤٦) 
٣٫٥٤ 
(٠٫٤٢) 
٣٫٦٧ 
(٠٫٤١) 
٣٫٦٦ 
(٠٫٤٣) 
٣٫٦٥ 
(٠٫٥٥) 
٣٫٧٣ 
(٠٫٥٢) 
٣٫٧ 
(٠٫٥٤) 
٣٫٨٤ 
(٠٫٤٣) 
٣٫٧١ 
(٠٫٣٩) 
٣٫٧١ 
(٠٫٤٨) 
٣٫٧٧ 
(٠٫٣٧) 
٣٫٦٦ 
(٠٫٣٦) 
Control 
 
٣٫٧٦ 
(٠٫٦) 
٣٫٦٨ 
(٠٫٤٦) 
٣٫٧٨ 
(٠٫٣٦) 
٣٫٧٤ 
(٠٫٣٥) 
٣٫٦٤ 
(٠٫٤٥) 
٣٫٧٦ 
(٠٫٣٩) 
٣٫٧٥ 
(٠٫٣) 
٣٫٦٢ 
(٠٫٤٢) 
٣٫٥٤ 
(٠٫٢٦) 
٣٫٥٧ 
(٠٫٣) 
٣٫٥٨ 
(٠٫٣) 
٣٫٥٨ 
(٠٫٢٨) 
P-value 
  
٠٫٢٥٤ ٠٫١١٥ ٠٫١٣٢ ٠٫٣٦٠ ٠٫٩٤٥ ٠٫٨٤٦ ٠٫٤٤٤ ٠٫٠٢٥ ٠٫٠٢٨ ٠٫٠٩٤ ٠٫٠٧٢ ٠٫١١٥ 
 
 
Table ٤٫٣٠ Blood Glucose 
Group Blood  glucose levels 
[Mean (SD)] 
 Baseline ٢wks ٤wks ٦wks ٨wks ١٠wks ١٢wks ١٤wks ١٦wks ١٨wks ٢٠wks ٢٢wks 
TOM 
 
١١٧٫١٩ 
(٥٠) 
٩٥٫٦٥ 
(٣١٫٧) 
٩٥٫١ 
(٢٤٫٣) 
٩٤٫٦ 
(٣٣٫٦) 
١٠٨٫٥ 
(٤٥٫٥) 
٩٧٫٢ 
(٣٢٫١) 
٩٥٫٧ 
(٢٨٫٧) 
٨٩٫٨ 
(٣٤٫٩) 
٩١٫٩ 
(٢٤٫٥) 
٩٤٫٩ 
(٣٢٫٤) 
٨٩٫٠٢ 
(٣١٫٤) 
٩٢٫٦ 
(٢٩) 
Control 
 
١٠٩٫٤ 
(٤٢) 
٩٧٫٣٣ 
(٢٧٫٣) 
٩٨٫٤ 
(٣٢٫٨) 
٩٣٫٣ 
(٢٢٫٥) 
٩٨٫٢ 
(٢٠٫٤) 
٩٣٫١ 
(٢٠٫٦) 
٩٤٫٦ 
(٣٣٫٧) 
٨٩٫٢ 
(٢١٫٣) 
٩١٫٣ 
(٢٤٫٥) 
٩٣٫٦ 
(٤٤٫٢) 
٨٧٫٣ 
(١٦٫٥) 
٨٦٫٢٣ 
(١٣٫٣) 
P-value 
 
٠٫٦٥٨ ٠٫٦٨٨ ٠٫٥٥٩ ٠٫٧١١ ٠٫٩٠٥ ٠٫٤٢٥ ٠٫٩٣١ ٠٫٧٣٧ ٠٫٤٣٠ ٠٫٨٢٩ ٠٫٢٠٦ ٠٫٣٧٤ 
 
 
٤٫٤ Conclusion and Recommendations 
 
 
The results of this study showed that family history asthma and atopy, allergic rhinitis and skin allergy 
were common in the majority of the study population. The main source of drugs was the pharmacy, but 
the main provider of patients’ counselling was the physician and this means that pharmacists do not take 
their responsibilities towards patients’ care. 
 
Both groups in this study demonstrated improved outcomes during the study period; this may have tended 
to reduce the apparent effect size of the pharmaceutical service. A number of factors could be at work 
here. The most important one is the fact that the identification of the drug-related problems in the TOM 
group and their discussion with the physicians have improved their prescribing patterns and they have 
implemented the majority of these interventions to the control group providing some new care practices.  
 
The pharmacist led-interventions resulted in improved final and intermediate patients’ outcome measures 
in the TOM group. The pharmaceutical care intervention has shown an improvement in the management 
of the asthmatic patients. The results support the value of collaboration between physicians, pharmacists 
and patients, which improved prescribing, solved drug therapy–related problems and improved the quality 
of care for asthmatic patients. 
 
Acquisition of the required clinical pharmacy knowledge and skills enables pharmacists to advise on the 
clinical use of medicines; to promote good prescribing practice and cost effective drug use; and to 
educate, counsel and advice patients on medicines and health Care. These results are important for 
implementing pharmaceutical care program through the government policy, which would cost-effectively 
improve the health status, clinical and psychosocial outcomes and quality of drug therapy. 
 
The recommendations that are suggested from this study include the following: 
 
 
Health managers, physicians and pharmacists in Sudan should be able to remove the barriers to 
implement the practice of pharmaceutical care that will increases the likelihood of positive health 
outcomes. 
 
Pharmacists, health managers and physicians should adopt the pharmaceutical care practice national 
standards. These national practice standards should be clear including unambiguous set of performance 
and expectations that are relevant towards improving patient outcomes, and feasible to implement.  
 
Continuing education programs for the pharmacists should be planned to stress the professional, legal, 
economic and moral benefits of pharmaceutical care. 
The faculties of pharmacy in Sudan should modify their undergraduate curriculum to meet the expanded  
role of the pharmacist. 
 
The challenge is that pharmacists have to prove that what they do is worthwhile, thus local research 
methods in evaluating pharmaceutical care should be carried out. 
  
Well-equipped specialized asthma centers with well-trained staff and effective tools of patients’ education 
and monitoring should be established for better disease control and quality of patient care. 
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 (A) Demographic data: - 
 
١-Date: 
٢-Name: 
٣- Age: 
٤-Weight: 
٥- Height: 
٦- Gender: 
a) Male                             b) Female 
٧-Occupation: 
٨- Residence: 
٩- Education level: 
١٠-Address: 
 Tel: 
 
(B) Patient’s medical history: 
                                                            
١-Asthmatic for how long: 
 
٢-Patient knowledge about asthma: 
 
٣- Frequency of acute attacks per week 
: 
٤- Frequency of nocturnal Symptoms per week:  
 
٥-Severity of asthma: 
 
   a) Mild:                    b) Moderate:                           c) Severe: 
    
٦-Number of admissions for the last six months: 
 
٧-Length of hospital stay: 
 
٨-Days of sickness per week: 
 
٧-Risk factors: 
a) Smoker:                    For how long: 
 
b) Non smoker: 
 
c) Stopped smoking:                        When: 
                     
٩-History of allergy: 
 
a) Yes:                             b) No: 
 
c) If yes specify:  
                         
١٠-Family history of asthma: 
 
a) Yes:                          b) No: 
 
١١-Family history of atopy: 
 
Yes:                             b) No: 
 
 
١٢-Presence of concomitant diseases:  
 
a) Yes:                         b) No:           
                                                                         
b) If yes specify: 
 
 
Diabètes:             Drugs: 
  
Hypertension:           Drugs: 
  
Ischaemic heart disease:             Drugs: 
 
Malaria:                             Drugs: 
 
Others:                  specify: 
 
Drugs: 
 
  (C) Management of asthma: 
 
١- Non-drug therapy measures: 
 
٢- Drug therapy and patients knowledge about their drugs: 
 
 
 Drug Preventive Rescue Doses 
١     
٢     
٣     
٤     
٥     
٦     
 
٣-Source of the drugs: 
a) Pharmacy:                b) Others:            Specify:   
                                                                                                                         
٤-Provider of the counseling:  
 
a) Pharmacist:                         b) Physician:                         
                                           
b) Self:                 d) Others:              Specify: 
                                            
                                                                               
٥-Accebtability of nebulizer use:  
 
a) Yes:                 b) No:                If no why? 
 
  
٦-If yes:                   a) At home:                          b) At hospital:  
 
 
٧-Cleaning and disinfection’s of nebulizer if used at home:  
 
a) Yes:                       b) No: 
 
c) If yes how: 
 
٨-Accebtability of using inhalers: 
 
a) Yes:                           b) No: 
 
c) If no why: 
 
٩-Score of inhaler technique: 
 
١٠-Monitoring of asthma: 
a) Patient knowledge about Peak flow meter: 
 
                           b) Clinically 
 
c) Symptomatic self-monitoring: 
 
١١-Assessment of side effects: 
                                                       
  Side effects 
No Drug Subjective Objective Biochemical 
١     
٢     
٣     
٤     
٥     
٦     
٧     
٨     
٩     
١٠     
 
 
 
 
 
 
 
 
 
 
 
 
FOLLOW UP CHART: - 
                
Outcome 
measure 
Baseline ٢ 
wks 
٤ 
wks 
٦ 
wks 
٨ 
wks 
١٠ 
wks 
١٢ 
wks 
١٤ 
wks 
١٦ 
wks 
١٨ 
wks 
٢٠ 
wks 
٢٢ 
wks 
Frequency 
of acute 
attacks/week 
            
Frequency 
of nocturnal 
symptoms / 
week 
            
Frequency 
of using β٢ - 
agonist 
            
Days of 
sickness 
/week 
            
Score of 
inhaler 
technique 
            
Treatment 
compliance 
 
            
PEFR 
 
            
Side effects 
 
            
Drug 
interactions 
 
            
Disease 
knowledge 
 
            
Drug 
knowledge 
            
Non- drug 
therapy 
measures 
            
Clinical 
assessment 
 
P 
RR 
BP 
 
           
Serum 
potassium 
 
            
Serum 
glucose 
            
 
 
 
 
 
 
 
 Problems and Interventions 
 
Patient problems
Interventions Responses 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
